2024-09-30-accounts

The British Society for Haematology (Limited by guarantee) Trustees, report and consolidated financial statements Registered Company No: 02645706 Registered Charity No: 1005735 Year ended 30 September 2024

The Brltish Society foi. Haemalology (Liinited by guai'antee) Ti'ustees. i-epoi-t and £onsolid8tcd financiAI statenients Year ended 30 September 2024 Trustees, repoit and adininstt'ative detaxls Indepcndent auditoiy, report to the inembers of The British So¢iety for Haematology (Limited by guat7ntee) Consolidated slateinent of fin￿]CIal activities (incorporating an iiicome and expenditure aeeount) Consolidated balance sheet 16 19 20 Coinpany balance sheet Consolidated Statement of Cash-flows 21 22 Not&s 23

The Britisb Society for Haematology {Limited by guai'aiitee) Trustees, report and consolidated fiiiancial statenients Year ended 30 Septembei. 2024 Ti"ustees' annual report The T￿SteeS present their annual report and the consolidated audited finaiicial statements for the Year ￿]ded 30 September 2024. These financial statements comply with CUlTent statutory requlleinents and wtdi the requirements of tlie charity's govaning document and with the Stateinent of Recommended Practice -"Accounting and Reportlng by Chai'ities" Objectives and Activities Tlie objects of the Society, whicli is a registered charity and conipany limited by gUa1'an￿e, are "to advaiice tlie practice and S￿dY of haematology atid to facilitate contact between persolls inlei'esled in haematology" Tlie chief ways in which the Socicty pui-sues these objects aTe thi'ough its journals. die pi'oduction of clinical guidelines, its Annual Scientific Meeting- its grants programme and educational nieetings and other I'esources. The Trustees confirni they have itfentd to tlie guidance froni the Charity Con)niission on public benefit and complied with the duty in Section 17 of tlie Chai'ities Act 201 I to have due regard to the Comniission's public benefit guidance. The Twstees confii-m that they have refeiTed to the guidance contaiiied in the Cliarlly Coinmission's gei)ei'al guidance on public benefit whet] i'eviewinE Ilie Society's aiins aiid Objectiv￿ and in planniiig fijlure activities. The Society's Mission Statenient places due emphasis on public benefiL with the sentence: 'BSH proinotes excellence in the sttidy, research and practice of haen)atology foi. tlie benefit of prof￿S10nals and the wider public" Details of Significant Activitics Tlie Society launclied ils revised slrdtegTC plan for 2024-26. As a membei3liip body, our woi-k is rnoi'e inipoi'lant tl)an ¢v¢i' iii tliis exciting and cliallenging time foi. haeiiiatology. As pait of our plan, we will build on tl)e aclii¢veinents we've made since 2019 l'egardiiig niullidisciplinary (MDD membersliip suppoit, knowledge sliaring> advocacy, and pai'tn¢rsliips. "Advancing the Society" will be our foui'lli strategic goal, overseeing the sustainability of oui. people, finances) goveimanc¢, and environment. Tile cui'rent stiategy's Vision and Mission Statements are.. Vision: To niake the study and practice of liaematology central to medicine and ensure tliat, tlirough tszining, reseai'cli aiid suppoit to oui. woi'kfoi'ce, people have access to tlie liigliest standai'ds of care and tseatment. Missioii: To be the leading membei3hip orgAnisatioll for all UK l)aematology professionals and an association through whicli they connect, share le21'ning, and pi-ovide a lliglily influential voice on all aspccts of liaeinatology. To promote excellence in the study, research, and practice of haeinatology for tJ)e benefit of professionals and tlie wider piiblic thLY)ugli: Multi-disciplinary ediication for sttidents and professionals at all levels. Raising standards of clinical care and laboratory practice tlirougli guidelines and experi advice. Supporting i'cseai'ch throiigh oiir publications. pi'ogrammes, and grants. Networking oppoi'ttinities that bring Iiaein profe￿lO￿alS togethei.; Repr￿C￿LIng the interests and concerns of baematolobry professionals at national and inteniational levels SLipporting our menibers across the duration of their careers Wellbeing iesources. Rcgi5tered Con1p￿]Y J)umber.' 02645706

The Brilisli Soeiety foi. Haem&tology (Limited by guai'antee) Trustees. report and consolidatod fin%ncial statenients Year elided 30 Septernbei. 2024 There are four straLegic aims for the three-year lifetÉme of the plan I, membei.ship suppoi't and engagenient: Increasing. diversifying. ￿}d valuing our members and volunteers, whilc pi'oviding valiie to them Knoivledge shai'ing.. through education. ts7ining, guidelines and supporting reseai'ch 3. Advocacy and partnerships: to enable a stronger mle in advocacy, reseai'cli, and collabotztion to adv8llce th¢ pi'a¢li¢e of Iiaematology Adv2Trelng the Society: by dtversifying income. creating the riglit infrastructure and eiiltw'e for people (staff & voluiiteers) we will support organisational resilience and flexibility to exteinal influences. In the plan, the Society is also coinmitted to inaking progress on EDI and iii tbe areas of enviromnental and operational sustainability. Tl)e plan is being followed up every six months with an update to the Board on progress Inade. Significaiit aclivities weir: The Ai)nual Science Meeting and other educa¢ional ev￿)IS Pi'ovision of the Bi-iÈi&Ji Joiii?ial ofHaeiiialology (BJHaeiii) and the open access journaI eJHllepii' Grant-nlaking progi'aiiime. Clinical Gukdeline8' Membership¥ Advocacy woi'k. We report on these items in more detail below. Menibei'sliip siipport and engagement: Meiiibei'sliip Wl)ilst nieinbei. nuinbeis are still inci'easing year on year, tlie Society is not coiiiplacent. Theit weir 3,242 men)beiB at Ili¢ year-end wliicli i'epL'esents a net increase of 312 meinbeis fron) tlie previous year (2,930). Gi'aiils awards diidprlzes Tl)e ¢ategories of awards are as follows.. Grant nAine Total avallable p¢r Maxlmuni per Appllegdiit student Electlve Scholarshlp8 Pool ot-£20,000 £ I,oIM) Trgvel Scholai'ships Amei'ican Soclety of Hematology Travel S¢liolgr.81)ips Eui'opean H4ematology As30¢iation Travel Scholarsbips Eai'ly-slage Resegrch Start-up grAnls BSH ASM Travel and Abstract Seholai'5hips Meeting Suppoi't grants 8 awards £ I,oix) 3 awards £3.0 10 awards £500 £40,000 Pool of £63,750 £1,000 5 awards £i.000 Visltlng Felloiv Scholarsliip l award £18,000 'alnee Education Bui'saries Pool of £10,000 £300 Global Haematology Scliolarship £6,000 Up to £50.000 pei. year to a total of £150,000 per project over the course of three years Up to £90,000 pei. year Cohort Study Ci'ant * l award SH fellows in Clinical AI * 2 awards Registered coD]pally numb¢r'. 02645706

The British Society for Haematology (Liniited by guai'aiitee) Trustees, repoi* and con501idgted financial statements Yeai. elided 30 Septeiiibei. 2024 The funds foi. these awards are from Designated Funds Further information oil the Erants prograin]ne is available on the BSH website. The Research and Grants Cotnmkttee oversees the grant applications that air not part of the designated fund, makes the awards, and reports back i'egulai'ly to the Tiijstee Board. Tlie Boai'd sets the grant-making strategy for the Society. (See also the section oil Designated Funds, with reference to the Data Registiy Fund). Iii September 2023 the Board designated funds to support two BSH fellows to Work, part time, foi. a yeai. on AI pi'ojects specifically aligned with clinical haematology. At the end of the year £270,106 worth of scientific grants had been awarded compared wÈth £ l 01,995 in 2023 (see Note 6). A total of108 grants were awarded compared with 76 in 2023. With tiavel restsiclions being eased now, mol'e traveL- related gi'ants were able to be awarded, including Triore support towards Global Haeinatology. Dui'ing the ycar the EArly- Stage Rescarcli (ESR) awai'ds w¢i'e reviewed after liavAn8 been put on hold: the figure disclosed in note 6 repi'esents a refuiid of balance Or￿.a)It unused {2023) and an ui)der-paynient adjustinent (2022). BSH continued with the National Institute for Health Research (NIHR) - BSH "Researcher of the Year" awai'ds and two awai'ds wei'e made tliis year which wei'c presented at the Pi'esidei)tial session al the ASM. BSH also awarded casli pj'izcs to thc lop two entries in its annual student essay coii)petilion to 8 total value of £750. Coiiiiiiuiiieulioiis Oui. reach via social media, e-bulletins and our website continue to grow. Oui. Jiiost popular social media ¢h8nnel is X {foiinerly known as Twitter) whicli has grown from 15,124 followers last year to 15,844. All oui. social media a¢¢ounts bave engagement from both l)aemalology professionals And patients froin ai'ound tlie world. BSH Ilas a l'ange of e- bulletins that inembers and non-menibers cai) sign up lo. the niost popular, at the tin)e of writing, beiiig: .Sul).sci-Ibtl'S Total Subsei'il)ei's Guldellnes 7,357 Events 6,103 Grants 5,309 2.232 Member-only Icnowledge sliai'iiig,, Annual Seientlfic Meetlng (ASM) The 2024 BSH ASM was lield as a face-to-face meeting at the ACC, Livetpool fiT)ni 28-30 April, witl) tlie Pilfalls sessions oll Satui'day 27 Api'il. Tbis was anotlier successful meeting wAtlI 1,842 delegates. Tlie ASM conti'ibutcd to th¢ subsidiai'y mal<ing a profit of £5 R2,160 fol tlie yeai.. Education 4lld awarcness Overall, die BSI.I speiit £1,557,952 on education and awareness activities COAnpared widi £1.379,530 iti 2023, with £133,966 being spent on a Workforce SuNey Pi'oject. Diii'ing the year die Society CODtsllbuted £37,500 as sponsoi'sliip of die Ajmual Sickle Cell & TbalassaemAa (ASCAT) event (2023.. £35,000) as well as spoiisoring tlie RCPatli Summer School with £1,500 (2023: £1,000), and the APPG on diveiEity and inclusion witli £2,000 (2023.. £2,000)- Educational events liave been deliveird both viitually and fac¢ to face. wKth virtual eveiits providing gi'eater flexibility & opportunities to tlie attendees. Tl)e Society has invested £133.233 in the BSH website during the year (2023: £116,026) Joifl'iials BSH pi'ovides the BJHaeni to all full and full (reduced) m￿nberS at a cost to the Society of £120,269 (2023.. £108,555). JHaeipi is co-owned by the Society and the piiblisber Wiley. The Society and Wiley also co-own an open access jouinal. Haeiii, wliich bas enabled Ibe publication of additional quality Mat￿￿al as a valuable overtlow from BJHaeni,' tbe Society received £76,839 in royalties from eJHaeiii dwing the year (2023: £77.119). Registered ¢oinpLny number.. 02645706

The Britisli Society for Hiemalology (Liiiiited by guarAlltee) Trustee5' repoi* And eonsolidated financial slatcniellts Year ended 30 Septeiiiber 2024 E)ieiits The Society ran five face-to-fice and four virtual education events throughout tlie year, via ils Educatioll Committee and Special Intei"est Gi'oups (SIGS). The events were across a wide range of subjects, and across a vai'iety of audiences, including students and trainees. ilul Ediicoli07t Tlie Education Team {slaff and volunteers), via a systrm of sub-edilors. ensure that the website is up to dat¢. The Cominittee has 8ppi.oved a iiumbei- of new case repoi'ts aiid haeinatology images for publication oil the site. The Cominitlee has also written a number of Muliiple-choice Questions based on recently published BSH guidelines and good practice papeiB which Iiave been added to tbe question bank on the website. The review of all educational mateiial published is ongoing. Tlie Society investinent in tlie Ixaining Management System (LMS) had b￿n postponed in 2022 due to staffmg and technical issues. The first coutse on transfusion, designed by volunteeiy on tbe Fducation Committee, is due to go live in late 2024. Clinical Guideliiies The Society's Guidelines Executive Committee and its four Task forces continued to pi'oduce high quality clinical guideliiics which iiol only support the liaematological coiniiiunity in the UK, but are used woi'ldivide. The Guideliiies Execiitive Coinmittee has also pi-ovided haeiiiatologi¢al advice to the National Institute for Health and Clinical Excellcnce (NICE) and olh¢T oi'ganisations, such as MSF. The Guidelines Executive Comiiiitlee recruited four trainees, 01)e for each task force. The trainees have a one-year lenui'e aiid are nientored by a task (oice member. They will participate in all tlie task foiee tasks, reviewing widelines, pj'oposals aiid participating iii guidelines writing groups. This lias been highly successful, and tl)e Society have reciuited the iiext 8el of trainees for January 2025 Tlie cost of tlie pi'oduction of guidelines was £61,741 (2024: £61,050). Tlie Society lias continued to produce Oood Practice Papers. Addeiida aiid Position Papers in addition to tli¢ fvll Guidelines. Tlie Society published its first Position Paper in January 2020. 'Red blood cell specifications for patients will) haemoglobinopatliies. a systeinatic review and guideline" Tlie Society produced twelve Guidelines, seven Good Practice Paper (GPPS), aiid one Addendum duiing the year. Many of the i'ecently publisl)ed guidelines have an audio cotnmenlaiy (podcasts). Tiiese l)ave proved extrenjely popiilai.; download figures given below. Links to tlie audio commenlaiies al'e available oli Ilie BSH websit and on PodBean. Fi'oni January 2021 the audio cominentai'i¢s are available to download, Podcast Downloads for 2024: 26,800 downloads - an increase of 141)/o from 2023. t) Jin I,X021-Dec3I.2￿4 26.8K t14% 1.21trd. Dec 31. 202a 1.500 Uke5 312Z Jao2OE4 IAr 2024 fv142024 Ju12024 Registered con)p8ny ])umber.' 02645706

Tlie Bi'itish Society for Haem2tology (Limiited by guavAiitee) Trustees, report and consolidated financial statenients Ye*r elided 311 Septenibei. 2024 Podcast Downloads from 2021 to 2024: The CJuidelines, GPPS and addenda issued during the year were: Geneyal Haematology Task Force Good Pi'ciclice P&pei 31 July 2024 Preveiition and mana Ihalassaeii)ia ei)ieiii of iiidwelliii calheter-relatcd ihrombosis in sickle cell di8ease aiid Giiideliiie.. The Mana 2024 Prevenlioi) ai)d ti-eatmeni ot. infectioii iii 2024 TS)e dia iiosis and iiiana Haen)ato-Oncology Task Force ¢menl t nce tioii and Pi n&nc in Thalabbaeii)ia S ildi'onies (+ podcast). Published 7 May )atiei)ts witli on abseiit oi. li ofunctional s leeii. Published l O Api'il eniciit of adult a lastic anaeii)ia. Publislied 21 January 2024 Good Pi'aciice Papei.: Assessinenl of fitiiess t"oi' blconi ciii u and iiiaiia enieii( of bleoiii classical Hod kiii I iii lioiiia, Publislied 6 November 2024 Advanced iii)a in for eai'lier dia aiid i)ioi'bidit i¢vcntioii iii inulti 2024 Ccntral iieivous s h laxis in lar Dia iiosis and initial Ireatiiieiit of Ii'aiis Dia iiosis and iiiana enieiil of siiiould¢rii) 2310212024 nai ioxici ati¢iils witli eloiiia. Publislied 9 Septcnibet. stem e ljthcell I lioiiia. Publislied I l August 2024 iblc hi li-risk in eloiiia atients. Published 23 Febrnaiy 2024 ilia {+ podcast). Published: Giiideline.. eiDei)t ofiiewl dia Haeniostasis & T￿.0MboSIS Task Force nosed lar e B-cell I hoina (+podcast). Published 21 JanU￿.Y 2024 Tlie assessi)ieni ￿ld iiiaiia emcnl ot bleedi risk Guideline for Laboraloi Dia iiosis and Moiiilorii) Uiiiled ILin doin Ha¢iiio hilia Ceiiir¢ Doctor's Or LVWD . Published 26 March 2024. C.ancei'_associatcd veiious Iliroiiibosis iii adulis Publislied: 25 April 2024. Investi ation and Mana eiiithit of Anti hos holi 'd S ndioine APS . Publisl)¢d.. 19 July 2024. Dia iiijsis and Mi ana eiiiei)t of Rare C()a Ilatioii Disorders. Addendum publislied 6 August 2024. leasureinent of h¢ aiin direct oral aiili-coa ulaiits and oibei. noii-couii3arin anli-Loa ulallls tSieii' eff¢¢ls ()ii liaemostasis aibkl A British Societ for Haeinalolo Guideli￿¢. Publisbed: 02 Septerllber 2024. rior to invasive rocedures. Publislied 22 March 2024. of von Ivillebi'and Discase.. a Joiiit Guideliiie fi'oni t]ie aiiisalioii ai)d the Bricisl) Socie toi Hauillulolo ' second edition A Britisli Socicl t.or Haeinalolo Guideliiie. RegiSt￿.ed company number.. 02045706

The Bi'itisli Society for HaemAtology {Lilliited by guar2ntee) Trustees, report and consolidated financial statements Year ended 30 Septeiiibei. 2024 TranSfi￿lon Task Force. Red Cell Ti'aiistiision iii Sickle Cell Disedse Part I and Red Ccll TL'ansfusioii in Sicklc Cell Disease Part11. Addendum Published: 12 January 2024. full guideline update cuirently in developinent Giiideliiie.s toi. the s ecificalion iiii leiiienlalion and inana laboiatoi'ies. Published: 24 January 2024. Guideline on tlie usc of l-ede osil autolo [d￿lt]fIcatIon aiid Maiia4Temcnt ot"Pieo eiiieilt of IT s sIci118 jii hos ital tk'aiisfusion ous donation. Published.. 25 Apiil 2024 ei'ative An&eirJia iii Adulis. Published.. 25 Apiil 2024. The Guidelines Task Foices collaboration with the Education Comirftittee, is on hold. Discussions contÈnue on furthei. collaboration in 2025. The Society, as part of its sti'ategy, has maintained the guidelines programnie budget for literature searches and tiie biidget foi. other services pi'ovided by medical writers. Advocacy and paitnerships Advocacy The 2019 BSH Workforce Report, plus the 2020 membei'ship survey, highlighted (he inci'eased pressui'es on the entii'e liaeii)alology woi-kforce and workfoire issues wei'e seen as a majoi. concem for the inenibership. BSH, aftei. a tender pi'ocess, appoint¢d London South Bank University. in a gi'oup headed by Prof. Alison Leaiy and Di.. Adele Stewart-Loi'd, to look at th¢ee areas of the liaematolo£y workforce: Workforce gap analysis Pi'aclitioner wellbeing Idei)lification of solutions and improvements As of Sepleinber 2024, tlie data collectioii and an31ysis liad been ¢on)pleted on Ille fii'st two areas of woi-k listed. Peei. Irviewed publications are being pwepared and a webinar sharing initial discussions lias been viewed over l 000 times. Tlie coll¢ction of solutions and improvements is ongoing. BSH advocate for their membership via: Woi-king witli otl)er organisations, for exaniple: Continuing to support wo1 by the RCP oil their two campAigns"strength in numbers" and"Tnequalities in Health Alliance" Pi'onioting Iiaematology as a specialty tluough the RCPatl) summer school foi. Inedical students Representation at relevant stakeholder meetings, Attendaiice al i'elevant exlilbitions sucli as at the Haeintology Patient and Carer's Coll￿.esS Engaging witli parlianienlary groups such &8 sponsoring tbe APPG on Diversity and Inclusion in STLM and atlendsn8 APPG on Sickle Cell and APPG on blood cancer meeting& Advancing the Society Oui. open rates aveige a150.9 0/0, whicli is well above the industiy average (35.8. /0); GA4 reported 611,870 views, of whicl) 154,554 were for the Giiidelines page, showing tbat, as in pi'evious years, tlie Guidelines remain tbe inost used website i'¢soui'ces. It should be noted tIMt in Deceniber 2019 BSH had ti) implelnent a new cookies policy as part of GDPR compliance which tneans website iisers Jnust opt in to be tracked illstead of opting OUL so ¢h¢s¢ niimbers only ieflect tl)ose who have opted to be tracked. The Society's CMS ceased to be supported in September 2023. necessitating essential and extensive upgrades to the website. For tlie Society to hfyst more educational videos, the hosting capacity was increased. Registered ¢ompany iiumber- 02645706

The Britisli Soeiety for Haernatology ILiIiiited by guai'xntee) Trustees, report and consolidated financial 5tatenientS Year ended 30 SepleiDber 2024 FinaLice The Boai'd continue to review how more of the reserves might be used for projects in ￿rth￿Wice of the Society's chai'itable aims and objectives. Éi'aiisuclioiis uiid iiiuiiciol The Tiustees are satisfied with the group's results for the year which are sliown in the coiisolidated staten]ent of financial activities and incoine and expenditure account on page 19. The Society has inCu￿ed no financial costs in any fundraising activity. Neither did the Society engage any external fundraisers, nor did it recetve any cojnplaints in respect of its fundraising activities. The Finance, Audit and Risk Cominittee Inonitors all financial aspects of the Society including its trading aim and the investsiieiits strategy and performance, Income Tlie total collsolidated incoine for the yeai. was £3,298,227 (2023.. £2,840,236). The biggest income stream remains tlie share of tlie profits of the Bi'ilisli Joiiiyial of Ht7enial0lo￿ (both BJHneFn & tlJaeiii) whicli was £1,068,978 (2023.. £1,093,573). During the year, the impact factor of Ilie BJHaepK was 8.615. it coiilinues to appear in the top quartile of haematology journals. The slHaeiii is now iii its third yeai. and ¢ontinDes to grow, with royalties of £76,839 being paid to the Charily iii the year, in relation to the Joui'nal year ended De¢eniba' 2023. The Society Cotitinues lo monitoi. thc Joumal finances and the foi'ec&8t for this year reiiiains conservative. The success of tl)e ASM in April 2024 produced £1,539,731 of toral income. Inconie fiom niembership subscriptions ivas £260,466 (2023., £243,874), will) an increase in subscillptioii Lates being impleniet)ted in January 2024. Tlieie were 3,242 active meinbers at Ilie year<nd whicli irpresents a net inciease of 312 membeiE from the previous year (2,930). Investment income was £162,681 (2023: £139,082) reflecting tlie improved intei'est rates and niarkets in tlie year. Tlie miniiiium irseives, as slated in tlie Investment Policy, liave been retaiiied witliin tjie Coutts Investnient poiifolio, wlii¢li continues to I￿aIntaIn a defensive strategy. The Society shows dividends reinvested ii) tlie Investment Portfolio as income dui'ing Ilie year tliat il received. I xpendltui'e Most i'esoui'ces expei)ded weir for tiinniiig tlie Society, running of the &nnual confei'enee, edueatTonal services, pi'oviding the Joui'nal to ineinbers ai)d f￿¢21'Ch grants. Granis ai'c recognised irt ihc Siat¢ment of Financial Activilies wlien they al'e autboris¢d by the Researcli and Grants Comrnittee. See above, Significant Activilies and Notes to tlit accounts foi. detailed Itporting on ￿'antS and education xs well as details on die inain streains of expenditure. The U'ading subsidiaiy results are dis¢uss¢d below and at Note 9. Designated Funds T&ie WilkiJ)son Beqiiest conlfinues to support tlie provision of tl)e Sir John Dacie Lecture by an intei'national speaker at tlie ASM iii conjunction with the RCPath. Costs associalcd with tliis lec￿re in 2024 amounted to £663, A maximujn of £90.000 has been set aside to support two BSH fellows, pait l&ine, for a yeai. oil Al projects specifLcally aligtted with Clinical haeD￿to10gy, WAth scope lo extend this furtber after reviewing its sUcC￿s. n 2020, tbe Board also designated £20k to be spent over two years on regional events and education. Tlie ￿lld was due to i'oll out during 2020 with the Researcli 2nd Grants Committee adininistering it. However, because of Covid-19 tliis was placed on bold and no thnds have been spent. Tl)e iemaining balance of £70,312 on tlie Workfo￿¢ designated fimd will be Ca￿led forward 8lld allocated for ￿rther research work witli London Soutl) Bank University on liaison liaematology. an ￿ea of work that liad been identifled as being uiidefined and unseen within the wider workforce researcli. Regista'ed conipany iiumbeT'. 02645706

The British Soeiety foi. Haematology (Liniiled by gu%i'antee) Trllstees, report 2nd eonsolidaled fingnciAI statements Year ended 30 Septenibei. 2024 Tradlng activities The Charity's subsidiaiy company inade an overall profit for the year of £512,160 (2023.. £428,797) aiid the results are shown iii note 9 to the financial statements. Resei'ves poliey The assets of the Society included tangtble fixed assets £390,371, investsneiit8 of £9,247,293, iiet current assets of £2,805,6S l and ovei?11, the Society's net assets stand at £12,443,315. This iiicludes desigtiated filnds of £201.338 and i'ests'icted funds of £266,371. During the year total funds inci'eased by £1.289.521 to £12,443,315. The Finance, Risk and Audi Committee continues to monitor the Charity's Reserve Policy annually. The level of the Opeixtional Reseive continues to cover 1.5 Ye￿ of running costs should li be neCeSS￿'Y to wind down Ihe Society for aiiy uiianticipated reason or if futui'e income falls. plus aiiiounts to cover flu¢luating ASM surpluses aiid the unlikely (but if it occuri'ed, daniaging) dramatic. unexpected loss of sponsorship incoine foi. the ASM. An allowance of 200/0 for mai'ket volatility was agreed, iesulling in an Operdtional Reseive figure of £2,550,000. In addition, Ihere should be a cash i'eseive of £500,000 at tlie year end to niaintain t]uidity; ple&£e see the tabEe below which shows tl)e short and long-term op¢ra¢ional reseives. Excludiiig opei'ational fixed assets, operational rescrves, restricted funds and designaied funds, suiylus reserves at JO Septelnber 2014 are £9 million. The Board regulai-ly propose designated fuiids be set aside for pi'ojects, in line with the Cli&rity's objectives, in order lo make use of the Society's surplus r&qerv&8. Purpose Amount (£) SEIOII'I I'Eldll I,'UNDS Operational casl) requirements al'e lield in accounts Witli Coutls and HSBC, as are tl)ose foi. BSH nterpi'ises. Shoit-tem) reseives are held in a Coutts Reserve account. Funds in excess of casliflow re uireinents are eriodicall moved to the investment ￿nds. £500k at tlie year end LONG TERM FUNDS Tlie Minimuin Reserye is nianaged as part of Investmenl Funds by Specialist Investment Managers witli same risk profile as fuiids itquired in 3-5 years. £2,550,000 TOTAL £3,050,000 Investment polley Investments continue to be managed according to tlie Investment Policy agreed in Jaiiuary 2019. During the yeai. tli¢ Boai'd alld Finance, Aiidit and Risk Committee agrccd lo rclain tlle miniinun] irserves level ivitliin the Coutts poi'tfolio - a low risk, defensive stt'ategy - and hold SU￿li1S funds widiin th¢ CCLA portfolto and COIF Deposit account tn oi'd¢r lo maximise investment inconie during the current m8rkets. Tlie ovei'all iiivestmenls mai'ket valiie increased by £1,128,571 in tlie year (2023.. £270,575). Tli¢ portfolios are aiined at gi-owth in value iatli¢r than income generation, widi incoine beiiig reinvest¢d. Tlie total investment portfolio was valued at £9,247,293 as of 30 September 2024, compared witli £8,118,722 in 2023. Investment income was £162,681, compared witli £139,082 in 2023, wilh dividends received and being reinvested witbin tlie Coutts investment portfolio being sl)own as inconie in the ye8r. Tlie fund managers 21'e adheiing to the restrictions imposed by the Trustees regarding ethical standai'ds. The pi'ogress of tlie investments is ts'acked and reviewed i'egulai'ly. The Trustees have taken advice from tlie invesunent managers and have invested in a range of investments and managed fl￿dS which meet tlieiT Anvesimenl ciiteria. Regular perforn]ance i'eports are received, and th¢ investsnent is reviewed on a r¢gular basis by the Financ¢, Audit and Risk Cojnmittee and by the Board, widi bolli CCLA and Coiilts presenting portfolio updates to the Finance, Audit and Risk Coinmittee at ils January meeting. Tlie Coutls Investment fund is defensive: the CCLA one is niedium risk. Regislercd company nW￿bcr." 02645706

The Britlsh Society foi. H2em3lolog)' (Limited by guai'antee) Trustees, Yepoi't and consolidated fingncigl stxternent5 Year ended 30 Septembei. 2024 Wliilst tlie Trustees al'e not complacent, they are confident that the Society's substantial rese￿eS will be enough to see the oi'ganisation through for the shoi't & mediun) tem) fvture. Investment powei's The Trustees have the power to invest ￿ndS not immediately required for operational puiposes in such concerns. securities oi. property as Ihey tliink fit. Pi'incipal risks and uncertainties The Trustees assessed the Society's risk iegister and the Dire¢tot3 of BSH Ente￿riSes Ltd assessed its iisk register ill September 2024. This exercise is uijdeitaken on an annual basis in accoi'dance with the guidelines foi. cliarities. FollL)wing the assessinenls, both documents wei'e revised and iipdated. The Tivslees of the Society and Directois of BSH Enterprises Ltd believe they have taken enough sleps ¢0 mitigate the risks identified for each organisation. The principal risks that the Society faces, as identified in Ilie updaled risk re8isler, are: Failut'e to translate strategy into achievable and ineasurable activiti&s Failure to ensure 11)at tlie ilew structures within BSH work together effectively: Major IT systems failure ii)¢luding failw'c withffin external suppliers. Potential financial losses, in particular fi'om the trading subsidiary due to drop in revenue from delegates at, or sponsorship of, the ASM. Below, we highlight the niitigation work to these risks. The Society is following its curiTnt Strategic objectives - supporting Ineinbers; knowledge transfer and advocacy - with The Board i'eceiving updates on the progi'ess of the sli'ategy twice a year, for effeclive nionilOI'ing. Tlie focus on advocacy willi a particular focus on work force is a new area foi. BSH and much of its efforts are on building solid fourtdalions lo better suppoit tl)e liaeinatology work force. A major pi'oject on work foi'c¢ is cui-rently undei- way, as not¢d in tlie Designated Flind Note 18. T]i¢ Society is fociised on ensiiring that S1￿cture {tl)e two Boards, Conimittees and Spectal Interest Groups) and i'esources (staff, building and nioney) are used oplinially io ensure Ilial the strategic plan will be acliievable and will ei)11211ce tlie cliarity's aims aiid objectives. The Society office team is now working in a liybrid officelhome fonnat, BSFI ¢onlinues to work witli its professional IT suppoit company lo maiiitaiii and iinpi'ove its Tcf infi'astructure lo ensui'e opliinal working efficiency and robustness. Tlie Society continues to inonitoi. and revi¢w its Disaster Recovery Plan, witli a pai-licular focus on IT systems failui'es. The chai'ity reinains a nece&sary source of ediicatioii and suppoit for the haeinatology profG8sion and niaterial 1055es in meinbers. subsci'iplions al'e not anticipated following the pand¢iiiic. The levels of subscriptions received in January 2023 were consistent with levels iii previous years, and there hav¢ not been substaiitial cancellations. Jolu] Wiley & Sons regularly update tli¢ Society on the finances of tlie Jouriials. Tlie 2024 ASM was a face-lo-face meeting in Liverpool, witii encourdging coiiJnercial support and regists'ations generatitig an overall subsidiary profit of £512,160. VAT Tlie Society continues lo inonitor its VAT stattis witli die assistance of its advisers and nMnagement accountant. Registered company number." 02645706

The Brittsh Socfiety foi. Haematology {Llmlted by guaJ'Antee) Tru$ttts' report and consolid8ted finai)eÉal stsitements Year ended 30 Septenibcr 2024 StrLiCtLll"e, govei"nance and inanageknent The oharlty is an incotyoi'ated legal entity limited by guarantee, the business ofwhich is governed by a Board of Trnstees, which meets quartei'ly. The chai'ity had 17 FTE staff membei's. this iiumber ineludes soine tempoi'2ry staff. Tbe staffing strnctui'e will be ievised ovei. the eoining year with lemporaty i'oles eÈther In(Ide peiinaneiit or, if covering a short tenn-pi'oject, ended. Trustees have delegated day to day i.espon8ibility for the rnnning of tbe charity to the Cliief Executive. Opei'ational inipri)vements: This yeai., we audiled our data process, processed records. updated our data protection policy, and trained slaff on data protection and securAng data. In the cotning year we will be U￿latIng oui. i'etention policy and implen]entation of deletion of records pi'ocedure. Tlie Noinination, Govei'nance and Award cominittee had iinplemented changes to committee recruitment to help streaiiilii)e and standai'disc the comniillee recmitmcnt process for team menibers ai)d volunteers, The society conducted an extensive review of our policies and pr(thlur¢s, which totalled ro 67. These are r¢vÉewed Illl'oiighout the yeai. on annual basis. We updated our ET policies and procedures and improved our IT account records to ensure they iiiatched oui. external IT provider's records. Since tlie expansion of our tcaiii, we have implemented ai) all-in-one HR system and acquired a iiew HR adniit) seivice fi'otn a tliii-d-party supplier. Our HR admin processes liave improved significaiitly tliis year, making il one of our biggest opeLatioiial acliievements. Tlie software lielps witIi siinple tasks by auloiiiatiijg reniindeis, keeping I'ecords, and i'equcsliiig annual leave. Employees and managei's liave acc¢ss to tlieii- own accounts to ieniind tliemselves of their details and records. Willi 11)e suppoil of HR consultants, we improved our oJ]boarding and offl)oaiding process, fleeing up oui. line managei's fL'om some HR adn)inistration tasks. BSH l)a8 been piloting 5UPPOrting volunteer travel by arranging ts7vel booking for successful gi'ant applicants and Global 14aem SIG overseas projects. As a result, we enlisted tl)e services of a tsavel nianagement company tl)at specializes iii providing seivices to non-pi'ofit organisations to a&8ist with booking travel. Spe¢lal Interest Groups and other groups The Society's seven Special Inlei'esl Groups are all active in their area, undei12king educational woi'k in vai'ious ways.. Global Haematology. Laboratoiy. Lymplioina, Myelodyspl&sti¢ Syiidrome (MDS), Obstetrics. Paediatric and Paedialric HaeniatoloEY Ii'ainiiig network sub81'oiip' and Teenage and Young Adults. The Society also lias an F.ai'ly CatEei's Folulll wl)icli is maktng excellent progres8 on tbe piloting of a inentoring scheme. Tlie BSH Boai'd agreed on 25 of April 2023 to admit tlie UK MDS Foium after the process of winding up Iliell. indepeiident cl)arity Witli the charity commission. UK MDS was adtnitted into tlie society as tlie new Special interest groiip llamed Myelodysplastic Syndromes (MDS) Special Interest Group. Tlie UK MDS Foiijni WRS & patient suppoit gi'oup that provided peer-to-peer support to people in the UK wEio have been diagnosed witli, or affected byy Myelodysplastic Syndromes (MDS) or Clironic Myeloinonocytic L¢ukaemi# (CMML). The Myelodysplasti¢ Syndronie (MDS) Special intei'est group is a network establislied by the Board lo educatg, ¢raiii. and develop healthcxi'e professAonRIs in UnderSta￿dIng, diagnosing, and inanaging MDS palienls. The MDS Special int¢re5t gi'oup will also build on tlie UK MDS Fornm's woi'k. Jlie UK MDS Foiuin was Eiven a legacy donation through a paltent that passed away from myelodysplastic syndroine and d]ese fi￿d8, along witli the i'eniaining capital from the UK MDS Fo￿ll1 chaiity account, were ts'ansfeiTed to tbe BSI.I and held in a Resti"icted ￿nd for tlie recently forn)ed MDS Special Interest Group. Tbe balance of tliis Restricted fund at tlie year end was £266,371. io Registered rompany nutnber.. 02645706

The Bi'itish Society loi- Haematology (Liii)ited by guarantee) Trustees, report and eotisolidated financial st3leniÈiits Yeai. tmded 30 Septembei. 2024 The designated Regional Events Fund, which irplaced the regional lead structure, has been on hold but the Board will review thi5 in 2025. The chaiity wholly O￿lS its tt7diiig subsidiary. BSH Ente￿)rises Liinited (BSHE), thi'ough which the organisation of the Annual Scientific Meeting (ASM) foi. the Briti&h Society foi" Haematology is conducted. Tlie coinpaiiy, BSHE Ltd, gift aids its taxable profits to the charity. The Trnstees of the chai'ity and the Directors of the subsidiary are responsi￿1¢ for strategic direction and govemaiice of the BSH and BSHE Ltd. The Key Management Pe￿Onnel of the group comprises the Trustees l Dii"ectors and the CEO. No Ti'ustees were J'emunei'ated during the yeai- {2023-. nil). Total relnuneralion to the Key Management Personnel was £318,703 (2023: £265,312). The pay of the Key Management Pei'sonnel is reviewed anllllally. In view of die nature of the chai'ity, the Trustees benclimai-k against pay levels in other charities. The remuneration setting policy is the mid-point of tlie l'ange paid for siniilar roles in similai-si7.ed charilies. Appointment of trusteesldii'ectors Elected Trustees/Directors are appointed by secret ballot of eligible men)bers during Febwary-march e&ch yeai" Oi'dinary Tivslees, the Secretai'y and the Treasurer sit for a three-year terni and the Vice-President Selv￿ ttvo years before becoming Pi'esidei)t and servitig a ￿￿ther two yeArs. Ordinary TNsle¢s, the Secretary and Treasuirr may stand foi. election for a second thiee-year teriii, thereby enabling theiii to serve up ￿ six yeai's on the Board in this i'ole. Tiustees take up/relinquisli office at the end of th¢ Aiinual Succession Board Meettng, either at the Tiustees, Meeting held dui'ing tlie ASM or vii'tually if the ASM is C￿}¢¢11cd or postponed. The Board lias the power to co-opt up to four Lay Trnstees, and these posts have now been filled, bi'oadeiiing the expertise available lo the Board. Tlie Society provides new Trustees with an indu¢tioii and guidance fi'oni tlie Cliai'ities Coiiiinis5ion and otlier relevant publicalions. Trusl¢es' i'¢niuneration and expenses at'e detailed in note I I lo the fLnancial slatemenls, Politieal and chai'itable contributions The group cannot make political contributtons under tlieir governing documents and charity law. Tlie gi'oup has not niade any cljaritable donations dui'ing the year. Futiii'e Plans Strategic Dii'ection Tlie four cun'ent aims are: l. ￿lembers11]p support and engagemellt: J?Ici easing, divei'sifying, and valui17g oui. niepnbei's and voliinleei's, while pi oviding valiie to iheiii. BSH will sutvey m¢inbei's and noii-members with a focus on understanding the needs of nurses, allied health pi'ofessionals, and scientists lo improve BSH membership offerings lo this growing seclion of the membei'sliip. Tliis will build on tlie knowledge gained from the 2020 survey to infonn oiir decision-making and ensure our inenibeiship benefits align witli IneinbeLE' needs. Reviewing meinbersliAp categories to help tailor benefils to better ineet oiw Jnembers, diverse needs. Introducing tiered Inembersliip Icvels with varying access to iEsources and events could enhance niember eng&gein¢nt. Review the Cohort Grant (pilot) to detein)ine its future as parl of Bsifs research funding strategy. Consider implementing Thon-scientific grallts to help with member wellbeing as well as considering proposals for new reseai'cli and training ￿7nts BSH will recruit a volunteei support officer so more support can be provided io the Specialist Intei'est Groups &nd their Inembers as the woi'k tliey do expands. li Registered ¢omp8ny number.. 02645706

The Brilisli Society foi. Haematology (Liiiiited by gu#i'aiitee) Trustefs, I'epoi't and roiisolidated financial stAteniellts Yeg1' ended 30 Septembei. 2024 2. Knowledge shai'ing: tlirough education, li'aining. guidelin￿ aiid supporling i'&seaicli. The plan in 202412025 is to expand education day events, evaluate the resourcing of the giiidelines team, strenglhen collaborations with the Eui'opean Haeinatology Associatioi) and ASH, review educalioii fonnats, develop a policy foi. engaging wÉth tl)e biomedical and pharniaceutical industry, and increase face-to-face atteiidance at fu￿re ASMS to sliowcase advances in haematology. 3. Advocacy and partnei'ships: lo e?iable a slrongei- Ivle in odvocllcy, i'eseaich, aiid colloboi'alioii to advaiice the pi'acttce ofhcienialologv. The Society aims lo deliver its workforce project, strengtllen partnerships, develop a strategy for people with haein&tological disorders, and develop a new policy for engaging witli industiy tILrough yeai'ly events and activities, while niaintaiiiiiig ii]]partiality. 4. Advanclng the Society.. by diveisifyiiig iiiconie, eiEatiiig ihe 17ghi iiifi'asliycluie aiid culiMI'efoJ'people (.glciff & voliiiileei's) we will Jiippoi'l oigaiiisalioiial i'esilieiic£ uizdflexibility lo ¢Ylei'iial iiifliieiices. The BSH aiiiis to itnprove volunteer rec￿ltDienC reteiilion, and recognition, and to engage the wider membei'ship. BSH coniiiiils to working towai'd beconiing a net zero organisation, implenienting a carbon reduction sti?legy and eiisui'ing t'enewable energy soui'ces for energy needs. Tlie oi'ganisation ensures best pi'actices in govei'nance. coinpliance, and opcrations by providing clear processes for voluiiteeis, iinpi'oving data systeiiis, incoiyoraling su¢c¢ssion planning, and cnllaboiating aci'oss sub-committees and special interest gi'oup coni¥Jiittees to iinprove service quality. A8SCSS Staff, volunteei's, membership, and activities for EDI baseline, identify schemes for achieving goals, and include EDI training ill mandatory training packages for stsff. Finanee The Board Continue to consider the ￿tUre use of surplus reserves and set aside Designated Funds foi. $pc¢ific purposes. Details of iliese funds are in iio¢e 18 to dle accounts. Tlie BSH is exploring potential inconie diversification tlirougli ￿ftdlng from tlje bioniedical and pliarmaceutical industiy, pooling resources, and niei'ging fvnctions, while itsearcbing tbe necessary pi'ocesses and i'esouices. The joumals continue to do veiy well financially. Like many othei. coinpanies, the jouiilals publisliers, Wiley. continues to assess scenai-ios as the global situation evolv￿ in ordei. to be prepared to adapt quickly. Membershlp Our niembersliip conlimies lo grow, especially tlie Associate inembership category, with niore nuiEes joining die Society and being actively engaged in ils governance with representation on inost of oiir comniittecs. BSRI will Continue lo invest in tlie membersliip package witli a focus on improving the benefits incliiding education resources, as well as advocacy woi'k and revi¢wing our grants programme. 12 Registered coinp2ny number: 02645706

The British Sociely foi. Haetnatology (Liiiiited by gtsai'antee) Trustees, report 2nd consolidated financial slateiiients Year ended 30 SeptenibeR' 2024 Statement of TLustees' respoiisibilities in respect of the Tiustees, Report and consolidated finaiicial statenients The Trnstees {who are also Directors of The British Society for Haematology for the puiposes of company law) are respoiisible for pi'epaling the Tiusteas, Report and the financÈal stateinents ITh aecordattct with applicable law and United Kiiigdom Accounting Standaids (United Kingdoin Generally Accepted Accounting P12Ctice). Compally law requires the Twstees to prepare financial statements for each financial year which give a tt'ue and fail. view of tlie state of affaiTS of the charitable coinpany and the group and of the incoming resourc&s and application of resources, including tlie income and expenditure, of the charitable group for that pthiod. In preparing these financial stateinents, tlie T￿sleeS al'e requÈird to- Select suitable accounting policies and then apply them consisteiitly- Obsetve the inethods and principl&s in the Charities SORP. Make judgements and estiniates that are reasonable aiid prndent. State whetliei. ai)plicable UK Accounting Siand3rds have been followe(L subject to any matei'ial departures disclosed and explained in the fii)ancial statements. Prepare the financial statements on ihe going concern basis unless it is inappropriate to presuine that Ilie charitable company will coiiliiiue in busiiiess. Tl)e Trustees are respoiisible for keeping propel. accounting records that disclose with reasonable a￿uracY at any time of the financial position of the charitable conipany and group and eiiable them to ensure that tlje financial stalen)ents con)ply with the Compani¢s Act 2006. They are also responsible foi. safe8uai.ding the a55els of the charitable coinpany and Ilie gi'oup and hence for taking reasonable steps for the prevention and detection of fraud and other irregulai'ities. The Ttustees al'e respoiisible for the inaii)teiiaiice and iIilegrily of the coiporate and financial inforiiiation included on the charitable con)paiiy's website. Legislation in the United Kingdoin 8overniiig the preparation and dissemination of financial stateiiienls niay differ froni legislation in other jurisdictions. In so far as we al'e awai'e.. Tiier¢ is no relevant audit infom]ation of wl)i¢li tlie Charitable company and group's auditor is unawai'e, and Tlie Trustees have taken all steps that tliey ougl)t to liave taken to make tliemselves awair of any i'elevant audit infoiThation aiid to establisli that the auditor is aware of tliat inforniation. ereiice aiid udiiiiiiis¢rfttioii iii oi'iiiatioii The Britisli Society for Haematology was irgistered with the Cliarity Commission on 7 November 1991 (i'egistered nun)ber1005735) and was incorporated as a company limtted by guai'antee (re8islered conipany nuinber 2645706) 01) 13 Septeiiiber 1991. The company is goveiThed by its Articles of A&sociatioii inc0￿01.ated oil 13 Seplembei. 1991 and which were last updated on 23 Junc 2023. 13 Registered compally ttumber.. 02645706

The Biitish Soeiety for Haernatology (Limited by guxi'antee) Trustees, report and eoiisolidated financial staleiiieiits Year ended 30 Sept¢nibei' 1024 Trusteesldlyectoi's The Ti'usteeslDirectO￿ who held office during the year were as follows: l October 2023 to 30 April 2024 30 Aprll to 30 Septombey 2024 Officers 14'esident J08h Wright (retired 30 April 2024) Dr Sue Pavord Vice President Dr Sue Pavord (retired 30 April 2024) Dr John AshciDft Ti'easui'er Dr John Ashcmft (retired 30 Aprij 2024) Mr Huw Rowswell * Seci'etary Prof Guy Pratt PIM)f Guy Pratt Ordlnaiy Ti'ustees Di. Cathy Burton Di. Subai'na Cl)aki'avorty Dr Cathy Burton Dr Subania Chakravorty Dr Christopher Dalley Mr Mark Ethell Dr Fioiia Miall Mr Mark Ethell Di. fiona Miall Mr Huw Rowswell * Prof¢ssoi' Jolin Snowden Mrs Laura Miller ' Sliankaianarayana Paneeslia Prof&ssor Johii Siiowden Laui'a Miller Di. Sliankaranarayana Paneeslia Co-opted Lay Trustees: Ms Kate Fieldiiig Dr Ttiai'indi Hapuaraclichi Pati'ick Keefe Mi. Keiil) Wai'd * Ms Kale Fielding Dr Tljarindi Hapuaraclichi Patrick Keefe Mr Keith Ward * * Menibei. of Finance, Audit and Risk Cominiltee At tlie end of 2023 tlie CEO left the BSH en)ployment, witli tlie newly appoitited CEO starting at the beginning of April 2024 The Trustees of Ilie charity con5tlttite Directors for the purwses of the Conipanies Act 21X)6. Registered company number: 02645706

The Brlllsli Soeiety f(¥Y Haematology (Liniited by guarantee) Trustees. i-epoi't 2nd con501idated financial statements Yearended 30 Septemhei. 2024 Registered office: 100 White Lion Street Finsbury London N19PF Adviser5 The compaiiy's principal advisers are as follows: Solicltors Bates Wells Brdithwaite l O Queen Street Place London EC4R IBE Clayden Law 1$¢ Floor, 22840 Banbury Road Oxford OX2 7B Y Auditors Haysmac LLP l O Que¢n Street Plac¢ London EC4R IAG Bankers Coults & Co 440 The Strand London WC2R OQS Investment Advlsers Church, Cliarity and Local Authority (CCLA) Fund ManageiB Limited Senatoi. House, 85 Queen Victoria Sli'eet London EC4V 4ET Coutts & Co 440 The Stfdnd London WC2R OQS Auditoi's HaysMaL LLP liave indicated their willinEness to be reappointed for anodier tem] and appiopi'iate an'angeinenls have been put in place for tlieni to be reappointed as auditoi%. In preparing tliis report, the Trustees liave taken advantage of tlie small companies, exetnptions provided by section 415A of the Companies Act 2006. By ordei. of tlie Board Huiv Rowsell TrustLe and Ti'eAsui'ei' 100 Wliite Llon Street Finsbuiy London N19PF Signed Date . tf./¥./.zs 15 Registered comparty nu￿ber. 02645706

The British Society foi. Haemalologs, (Limited by guai'alltee Tndependeiit auditol 5 l-epot't Yeai. elided 30 Sepleniber 2024 llldepeiident audltor's report to tlie meti)bei's of The Bi'itish ,Society for Haematology (Liniited by guai"aiitee) Opinion We have audited the financial statements of The British Society for Haeinatology for the Year ended 30 Septeinber 2024 which comprise the Slalement of Financial Activities, the Balance Sheet, the Statement of Cash Flows, and notes to the financial stateinents, including a suinmary of significant accounting polici&s. The financial I'epoiting fi'ainewoi'li that has been applied in their pi-eparalion is applicable law and United Kingdom Accountin8 Standards, includiiig Fiiuncial Repoi'ling Standard 102 The Financial Repoi"ling Staiidard dpplicable in the UK ond Republic of Jielciiid (United Kingdoin Generally Accepted Accounting Practice). In our opinion, the financial statements: give a t￿e and fair view of tbe state of the charitable coinpany's affaii's as at 30 Sepiembei. 2024 and of the chai-itable coinpaiiy's net moveiiient iii funds, including the income and expenditure, for the yeai. tlien ended- have been pi'operly prepai'ed in accordance with United Kiiigdoni Genei'ally Accepted Accounting Pl'actice,. and have been prepai'ed in accordance with the requii'ements of the Companies Act 2006. Basls for opillion We conducted our audit in accordance with Iniemational Standards on Auditing (UK) {ISAs (UK)) and applicable law, Oui. responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the rinaiicial statements section of our report. We are independent of the charity in accordaiice witli the ethical I'equii-enients that are relevant to our audit of Ilie fiJian¢ial statements in the UK, including the FRC'S Etl)ical Staiidard, and we Iiave fulfilled our other ethical responsibilities in accordance with these requÈrements. We believe that the audit evidence we lave obtaii)ed is sufficient and appropriate to pi'ovide a basis for oui- opinion. Concluslons i'elatlpg io golng concei'n In auditing tlie financial statements, Ive Iiave concludcd tl)at the tn￿tees. use of tlie going concei'n b&sis of accounting lll tlie pi'eparation of11)e financial statements is appropria*. Based on tlie work we liave perfonned, we liave iiot identified any nlaterial uncertainties relating to events or conditions tl)al, individually oi. collectively, may cast significant doubt on the ¢haiitabl¢ conipany's ability to coiitinue as a going conceni for a pei'iod of at lea8t tivelve months from wllen the financial statements are aullioi'ised for issue, Our i'esponsibilities and the responsibilities of the In￿tee$ with respect to going concern are desci'ib¢d in tile i'elevant sections of tliÉs report, Other Iiiformatlon The lijjslees are Kespotisible for the ollier inforn]ation. The otlier infonllation compi'ises d)e inforniauon included in the Trustees, Anniial Report. Out. opinion on tlle f￿anCIal statenients do¢s not cover tlie other infoiTration and, exc¢pt to tlie ext¢iit olheThvRse explicitly stated ill oui. i'epoit we do not express any fonn of assui'ance conclusion thei'eon. In connection witli our audit of the financial statements, our responsibility is to read tlie othei inforination aniL in doing so, considei. wbetber tbe other infomiation is inalerially inconsistent with the financial statenients oi. our knowledge obtained in the aiidit oi. oththwise 2ppears to be Iiiatei'ially misstated. If we identify such Enaterial illconsistencies oi appareiit inaterial inisstatements, we are required to detem]ine wliellier Ille￿ is a inaterial misstateinent in tlie fInancial statements oi a tnata'ial inisst2tement of the otlier infoTn)ation. If, based oil tbe work we liave perfornied, we conclude that t])¢r¢ is a material misstatement of this otjier inforni&tion, we are requir¢d to report that fact. We liave nothitig to report All this reg￿.d. 16 Registered coii)pany i)umber.' 0264570fj

The Biqtish Society for Haeniatology {Liiiiited by guaraiitee) Illdependenl Auditor's i'eport Year ended 30 Septeniber 2024 Opiiiioiis on otlier matters prescribed by the Companies Act 2006 In our opinion, based on the work undertaken in the cOu￿e of the audit: the infom]ation given in the Trustees. Annual Re￿rt (which iiicludes the strategic itPOTt and the dii'ectors, repoi1 PiEpared for the pwV0￿ of company law) for the fmancial year foi. which the finaiicial stateinents are pi'epared is consistent with the financial statements. and the stiategic report and the director5, repoil included within the T￿steeS, Annual Report have beeii pi'epaird in accoidance with applicable legal i'equiiements. Matters on whlcli we are i'equij'ed to report by exeeptlon In the light of the knowledge and underslandill8 of the charitable company and its environment obtained in the coiii'se of the audit, we have not identified matei'ial Inisstatements in the T￿Stees, lthnual Report (which i1]co￿orateS the stiategic report and the dii'ectors, repoit). We have notliing to ttporl in respect of the following n)atters in relation to which the Compaiiies Aci 2006 L'equires us to report to you if, in our opinion: adequate accountiiig recotrfs have Iiot been kept by the cliaritable company. or tlie charitable coiiipany financial statements al'e not in agi'eenient with tl)e accounting records and irturiis. or certain disclosures of trustees, reinuiieration specified by law are not made: or w¢ have not received all the inforination and explaiiaiions we require for our audit. or the twslees were not entitled to prepare the financial Slalements in accoi'daiice witli the sinall coinpanies, regiIne and take advantage of the small coinpanies, exempiiolls in prepai'in8 the Étijstees, i'epoit and fi'oin the IEquireinent to pi'epare a sti'ategic report. Responsibilities of trustees for the finonclal slatement$ As explained Inoi'e fvlly in tl)e tNstees' responsibilities statement set out on page 13, tlie trnstees (wlio al'e also tlie dii'ectoi's of tlie ¢liaiilable company for tlle puiposes of company law) ar¢ responsible for tlie prepai'ation of the financial slatenients and for being satisfied d)at Iliey give a true and fair view, and for sucli internal control as tlie tivslees deteimiine is necessary to enable the pi'eparation of financial staieinents tliat are free from material niisstateinent, wlietliei. due to fi'aud or eiTOr. In pi'eparing the financial stalen)ents, tlie tivstees are responsible fok. assessing tlie cl)aiitsble company's ability to Coiiciiiue as a goiijg Concei'n, disclosing, as applicabl¢, niatters i'elaled lo going concein and usiiig tlie going concern basis of accounting unless the tnEStees either intend to liquidate the chai.1￿ble coinpany oi. ¢0 cease operations, or have no realistic 8lteiiiative but to do so. Audltor's i'espollsibilities for tbe audit of the fin4nclal stxtemetits Our objectives are to obtain irasonable assurnnce about whether tlie financial statements as a whole are fi'¢e froiii inateriaR isslatcment, whetlier diie to fraud or enY)r, and lo issue an auditor's report that includes oui. opinion. Reasonable assurance is a high level of assiii'ance. but is not a guarantee that an audit conducted in accordance witli ISAS (UK) will alway5 detect a matei'ial niisstatement when it exists. Misstatemenls cali arise frokii fraud oi. eii'or and are considei'ed Inaterial if, individually or in die ag￿'e88Ie, they could reason&bly be expected to infliience Ihe economic decisions of users taken on the basis of th￿e financial slateinents. Ii'i'egiilarities, including fraud, are instances of non-coinpliance with laws and ￿gulatiOnS. We design procedures in liiie witli oui. responsibilities, outlined above, to delect material inisstatements in respect of in'egulai'ities, including fraud. The extent to whicli our procedures are capable of detecting itregularities, including fraud is detailed below- Based oil oiir iinderslanding of tlie charitable con]pany and the environment in ivhicli it operates, we Édefttified diAt the pi'incipal iisks of non-compliance with laws and regulations related to tlie Companies Act 2006 and Cliarities Act 2011, and we considered tlie extent to which non-compliance miglit bave a inaterial effect on the financi81 statements. We atso considered those laws and regulations that have a direct impact on the preparation of the financial statements sucli as payroll tax and sales tax. 17 Registered company number: 02645706

The Biitish Society for Haematology (Liinited by guAralltee) Independent auditoi s I'epoi't Yeai. ended 30 Septeniber 2024 We evaluated tiianagement's incentives and opportwiitios for fi'&udulent inaiiipulation of the fiiiancial statemeiits (including the i'isk of ovenide of controls), and deterniiiied that the piincipal risks were i'elated to postiiig inappropi'i&te jouii]al ents-ies to revenue and Inanagement bias in accounting estitnates. Audit procedures peifonned by Ilie engagenient teain included.. Inspecting correspoiidence with regulator8 and tax authorities. Discussions with management including consideratioii of known oi. suspectsd instances of non-coinpliance will) laws and regulation and fraud. Evaluatiiig maiiagement's controls designed to prevent and detect iiTegularities- Review of ininutes of meetings Identifying and testing jouinals, in particular journal entiies posted as part of the year end pi'ocess- and Challeiiging assuinptions and judgeinents made by managenient in their critical accounting estiinates Becaiise of the inhei'ent limitations of an aiidit. there is a risk that we will not detect all irregularities, including those leaditig to a m2tei.ial i￿l$staten1ent in the finaT)cial sl&tenients or non-cornpliance witli re8ulation. This i'isk inci'eases the mol'e that conipliance with a laiv or regulaiion is removed froin the events and tran.%actions reflected in the finarbcial statenients, as we will be less likely ¢0 become aware of instances of non-compliance. The risk 18 also greater Leg￿.dIng ii'i'egularities occuri'ing due to fraud i?thei' than effor, as fraud involves intentional concexlnieiit, foi'gay. collusion, omission oi. Inisrepitscniation. A fui'thei. description of our responsibilities for the audit of Ihe financial siateinents is located on the Finarlcial Repoiting Council's website at: www.frc.or .uklaudiloiEr¢s ililies. This description forins part of our auditoi s i'epoi't. Use of our report Tliis itpoit is made solely lo tlie cliarilable compaiiy's Inembers, as a body, in accordance witl) Cl)apici' 3 of Part 16 of tlie Companies Act 2006. Our audit woi'k lias be¢n undeitaken so rliai wc miglir Sthie to tlie cliarilable coInpany's membe1% tliose matters we al'e i'eqiiii'ed to state to tliem in an Auditols report and foi. iio oilier piirpo&e. To tlie fullest extent pei'niitted by law, we do not accept or assume responsibility to anyone oilier tlian the cl)ai'itable company and Ilie ¢liaritable con)pany's inembers, as a body, for our audit work, for tliis r¢poit or for tlie opiiiions we have foiThed. Tlionias Wilson (Senioi. Statutory Auditor) Foi. and on belialf of HaysMa¢ LLP, Statutory Auditor Date; l O Queen Street Place London EC4R IAG 18 Registei'ed company iiumber.. 02&15706

The Bi'itish Society for Haemglology (Limited by guai'antee) CoDsolidated statenlellt of fin3nci312etlv5tles Yeai. ended 30 Septeniber 2024 Gtner Funds Restrleted Funds Deslgthated Funds Total 2024 Total 2023 Not ]Nc0￿ FROM: Donatio cli￿1[abl¢ a¢tiwties= SJibscF'iptlOPlS 266,371 266,371 2C)0.466 1.068.978 260,466 1.068.978 243.874 1,093J73 35 1.363,672 139,082 Oil)er' ijictsiiie liicojiiefi'oipi Ilie CoiiJ*ieiiees InNtstin¢nl ill¢ome lJ39.731 162.681 1.539.731 162,681 TotAI Iiicome 3031856 266371 3,298,227 36 I XPENDlliiRE ON: Raising fut liiiJ8sliiieiil iii&iiageiiieJiilees 37.792 37,792 36,618 Chari¢llbl¢ a¢tivilies: Reseoreh Ediicrtllopi alid¢ElI￿}'t1Iess Cosl ofcoiifeieiieÉs 393,998 1,423.323 1.022,116 SI￿1S 134,629 445,573 1,557,952 1.022,116 290,056 1.379,530 929,373 Total 8ypÉndltui'e 2 877 229 186204 3 063 433 2 635 577 Net income befolf itINrstmei)t gains arKI Ir8msf¢x6 154,627 266,371 (186204) 234,794 204,659 Nel (Ioss¢5)l on inNtstments Net income aiid net in 1.054 727 1,209,354 1.054 727 1,289,521 207,813 412,472 266J71 (186.204) Trw18fcr betVAren fuTrJs Fund balafte&q blf 10.766252 38?J42 11,153,794 10,741,322 Fund bal8iic&q elf 11975606 266371 201338 12443315 11 153794 All re¢ogni5ed gains and loss¢s are reflected thi'ough the Sthtement of Financial Activities. All activitics reflected above are continuing activities. The acconipanying notes on pages 23 to 40 fonn part of the accouols. 19 Registered cotDpaiiy number.. 02645706

The Britisli Soeiety fol. Haeniatology {Liniited b), guarantee) Consolidated Balance Slieet At 30 Septeniber 2024 2024 2023 Note FIXED ASSE4lS Taiwible assets In￿SImCnts 14 15 390,371 9,247293 405,941 8.118.722 9.637.664 8,524,663 CURRENT ASSETS Debloi's Ca811 at bat)k and in hand 16 418.050 2 773,824 3.191,874 468,473 2 688 534 3,157,007 CREDrroRS.. Atnounls f011iug du¢ tliit) olle y¢ar 17 {386223) (527,876) N￿T CURRENT ASSETS 2.805.651 2,629,131 TOTAL ASSETS LEI SS CURRENTLJABILITLWS 12.443,315 11,153,794 NKT ASSEIS 12443 315 11 153794 UNRESIRICIED FUNDS: GcrKr81 fvllds R¢sti'i¢led funds D¢si8n8l¢d funds 18 18 18 11,975,606 266,371 201338 12443 315 EO,766,252 387,542 11 153794 Tlie fiiiaiicial slatemcnts were approved and aulhorised for issue by tlie boai'd of Truste¢s on and were slgned on its belialf by Dr Sue P8voI'd Trustce And President Huiv Rowsivell Trustee aiid Treasui"ei' Tlie accompanying notes on pages 23 to 40 forn] part of die accounts. 20 Registered company number.. 02645706

The Biitisli Soelety for Haeniatology (Llmited bj, gu&i'&ntee) Cliai-i*able Company Balance Slieet At 30 September 2024 2024 2023 Note FIXED ASSEIS Tangible assets InveSt￿entS 14 15 390,371 9.247,295 405.941 8,118.724 9,637,666 8.524,665 CURRENfASSEI3 Debtoi's Cash at bank and in hand 16 404,959 2.108,838 2,513,797 432,060 2,055 156 2,487,216 cRED￿oRs.. AmouDls fa]ling due wiiliin one ye 17 (375,273) 443 746 NETCURRENT ASSE18 2 138 $24 2 043 470 TOTAL IS LESS CURRENTLIABILITIES 11,776,190 10,568,135 NEI T ASSETS 11,776,190 10.568,135 UNRFSTRtCTED FUNDS: General funds Reslricled funiLs Designated funds 18 18 18 11,308,481 266,371 201,338 11,776 190 10,180,593 387,542 10,568 135 T]ie fiiiancial slat¢meiils were approved and authoris¢d for issue by d)¢ board of Trustees on and were d on its behalf by Dr Su¢ Pavord Trustee and President Huiy Roivsivell Trustee aiid Treasurer The accompanying notes form part of the accounts. As peiiDitted by Section 408 of tlje Companies Act 2006, no separate Statement of Financial Activities oi. Income and Expenditure account Eias been presented for tlie charity alone. Income of the paient charity alone alnounted to £1,928,272 (2023: £1,642,824). Net income of the charity after i'ealisedlunrealised gaÉns oll investments amounted to £1,208,055 (2tr23: £139,352). 21 Registered company sJun)bcT.' 02645706

The British Soclety loi. HJem¥tolo2y (L£inited by guarantee) Consolidated Cash filow Statement Yeai. ended 30 Septenibei. 2024 2024 2023 C4sh flom's from dperAtiDg gctivities". Net cash proNidedbyllused it]) opei'atiDg tjMties (1,411) 292,2¥2 Cash Ilow¥ Irthm Inv¢stlng acilrftles Dividends 8nd it]ierest PUrCh￿e of instments Proceeds from sale of inwilmenls {Inci'ea8e) in invcstn)¢nt wli Paynienls to acquire tangible fixed assets Net easliproyided by In￿St￿518￿Cl1vilLeS 162.681 (1,699,481) 1.635.986 {10,301) 139,082 (1,929,731) 1,732.812 134,157 86.749 71.470 Nel In¢rÈAse In eAsli And cAsli equlTal¢nts C&%1) CAsh equivaleiils at th¢ be￿llnIng of the re￿rtIngpel70d Forelgn exchange galns atld lossès on cash and cash eq￿￿￿[entS Challg¢ illcasb and c85h ¢qUi￿le￿iS in the reporting ￿rIOd 2.688.534 {48) 8S,338 2,324,782 363.752 Cash 4nd cosli équivalentl 8t tlie end of the i'eporilng p¢rlod 2 773 824 2 688 534 NOTEI S TO THE sfATEfvIENT OF ChSEI FLOWS (A) Reeoii¢lllgtloii of Net Movenient In Funds to Net Cwh Floil from Op¢ratlllg ￿tIVItIeS. Ncl I￿0￿Ine11t iii funds.. N¢1 88in on inNrsts])cnts Depre¢idlion Deere8sel{iThcre&gel in dcbtoi's icreaseIdeere￿e in creditors Dividcnds, iDleresls andr¢nl$ trom inNultnents ,289,521 (1.054,727) 17,706 50.423 (141.653) (162,681) 412,472 (207,813) 20,172 148,991 57.542 (139,082) Nel c851] pvovlded byl{used In) operntlnE gctlvlllts 292 282 (B) knIAlysls of Cash and Cgsh equi￿le￿I$ 2 773 824 2 688 534 The accon)panying notes fonn an integral part of these accounts, There were iio debt an'angements entered during the yeai.. 22 Registered colnp￿lY iiumber.. 02645706

The Britlsh SDeiety foj. Haematology {Li￿lited by guai'antee) Notes to Ibe fin%nci41 statenient5 Year ejided 30 Septettibel. 2024 COMPANY STA TUS The coinpany is limited by guai'antee, not havillg a share capital. The IneinbeTS undertake to contribute to the assets of the company in the event of it being WOUT)d up, either whilst members or within one year of the membersliip ceasing. The mAximum contribution i'equii"ed from each Lnember is £1. Their weir 3,242 active meinbels at 30 Septembei. 2024 (2023: 2,930). ACCOUNTtNG POLICIES Statement of compliance The fmancial statenients have been prepared in accoi'dance with Accounting and Repoiting by Charities: Stateinent of Recommended Practice applicable lo chai'ities prepariiig their accounts in accoi'dance with the Financial Reportiiig Standard applicable in the UK and Republic of Iielond (FRS 102)- (Cliarities SORP 2015 (Second Edition, effective l Januaiy 2019), the Financial Reporting Srandard applicable in the UK and Republic of Ireland (FRS 102) and the Compaiiies Act 2006. Assets and liabilities are initially recognised at historical cost or transaclion value unless otlienvise stated in the ielevaiit accounting policy notes. Gener81 liiformatfion The Cliarity is a company limited by 8uarantec, inCO￿orated in England and Wales (company iiuinbei.: 02645706) and a chai'ity registered in England and Wales (charity number.. 1005735). The Cliarity's registered office address 18 100 Wliite Lion Street. London N19PF. Tlie Bi-itish Society for Haematology meets tlie definition of a public benefit entity under FRS 102. Consolidatfion Tlie accounts consolidate tlie financial statements of The British Society for Haematology aiid its wliolly-owned subsidiary, BSH Enteiprises Ltd, on a line-by-line basis. Transactions and balances between tli¢ cliarily and its subsidiary liave been eliminated fron) the consolidated financial staten)ents. As permitted by Section 408 of tli¢ Companies Ael 2006, no separate Statement of Financial Activities of Inconie and Expenditure Account lias been pi'esented foi- the charity alone. Inconie of the parent charity alone amounted to £1,928,272 {2023'. £1,642,824). Net incom¢ of tlie charity aftei. Tealised/unrealised gains on investments ainounted to £1,208,055 (2023: £139,352). Goiiig collcern Tlie Trustees have reviewed Il)¢ Reserves Policy and tI)e foi'ecasts for tlic next two yeai's and consider that there al'e no inaleiial iinceitainties about The Britisb Society foi Flaeinatology's ability to continue in existence and it has adequate reSoiwC￿ foi the nw future. Cimrnt levels of investments and casli funds al'e in excess of die Reserves Policy and the Cbarity has the ability to curtail expenditure to a mininial level of overli¢ads. Every quarter the FARC reviews inanagement accounts, budgets, and 24 month cash pi'ojectiolls. The budgets prepared for the coIning financial year will carefully consider the control of outgoing expeiiditw'e to be in line will) the cli￿ent incojhe streams, any effwl on levels of income due to the pandeinic, and ally increases in income i'esulting from the projects to diversify and increase income. 23 Registered compally number.. 02645706

Tbe Bi'iti5h Soriety for Haematology (Llmited by gua*2ntee) Notes to the fjnancial 5tatenienls (coiiliiiiied) Year ended 30 Septciiiber 2024 ACCOUNTING POLICIES (continued) Crltieal accounting judgements and estimates and key sources of estlmation uncei'talnty In the application of these accounting policies, the Trustees are iEquired to make Judg￿￿entS, estiinates and assuniptions about the carying value of assets and liabilities that are not i'eadily apparent from othei. soui'ces. Estimates and judgements are continually evaluated and are based on historical expeiience and other factoi's, including expectations of fijture events that are believed to be reasonable under the circumstaiices. Although these estiinales are based on ll]aDagcment's b£st knowledge of the amount, eveiits 01- &clions, actual results may uliimately diff￿. from diose estimates. Revisions to accounting estimates ai'¢ recognised in the period in which the estimate is revised if tlie i-evision affects only that period or in the period of Ihe revision and futuir pei'iods if the i'evision affects cunrnt and ￿tUre periods. The Trnstees consÈder the following itenis to be areas subject to ¢stin)atioii and judgen)ent.' Depi'eciation.. The use￿1 economic lives of tangible fixed assets are based on mxnagement's judgcinent and experience. WThen management identifies th2¢ actual useful econoniic lives differ m2t¢rially from the estimates used lo calculate depreciation, that chai'ge is adjusted retrospectively. Altbough tangible fixed assets are stgnificant, V￿.lanceS between actual and eslimaled use￿1 economic l&ves will not have a n)aterial iinpact on tlie operatiiig results. Historically, no Clianges have beei) required. In the view of the Twstees, no assumplions eonceriiiiig the future or estimation uncertainty affecting assets or liabilities at the balance sheet date are likely to result in a material adjustnieiit to their canying amounts in the next financial year. Tlie following accounting policies have been applied consistently in dealing with items which are considered material in relation to tlje financial statements. Income All income is recognised wlien the criteria of entitlem¢n4 measuretnent and pi'obability of receipt have been satisfied. Membei'sliip subsci'iption incom¢ is accounted for on an accrual basis and i'epresents only tliat part of tlie subscription wliicli relates to Ilie financial year in wliich it is paid. Tlie balance is included in deferred income in ci'ediloi's on tbe balanc¢ sheet and released in tlie period to wliich it relates. Dividend iiicome is accounted for in the statement of financial activities in tlie pei'iod in wliich tlie chaiity is entitled to receipt. The profit Sh￿'C ieceivable from Jolm Wiley & Sons Ltd in respect of BJHaein and ￿Hael11 is r¢¢ognised on a i'eceivable basis. Turnover in BSH Enterprises Liinited represents the ainounts (excluding value added tax) derived fron) the provision of tlie annual conference for Tlie Bi'itish Society for Haeniatology. Turnover is accounted foi. on an accwal basis with income recognised in the profit Jnd loss account foi. the conference coinpleted in the ciin-ent accounting period. Deposits i'eceived in respect of Ibe confer¢nce in the next accounting peiiod al'e lield in deferred income ill creditors in the balance sheet at tlie year end. 24 Registered cot]]pally number.. 02645706

The British Soclety foi- Haematology (Liniited by guai'xntee) Notes to the financial stateinents (coiiliiiited) Year ended 30 September 2024 ACCOUNTING POLICIES {continued) Lxpenditure Liabilities ￿"e i'ecognised as resources expended as soon as there is a legal oi" constTUCtive obligation committing the charity to the expendituie. Expenditure is accounted foi. on an accruals basis and has been classified under headings that aggTegate all cost i-elated to the category. Where costs cai]not be diTectly attributed to partieular headings, they have beeii allocated to activities on a basis consistent with the use of resources. Expendituir is classified under the following activity headings: Costs of raising ￿rnds coniprise the costs of investnient managenient and odjer suppoi't costs that do not ielate directly to separate charitable activities. Expenditure on charitable activities includes the costs of piY)jects on health and education and their associated costs undertaken to furtljer the purposes of Ihe cliarity. Support costs have been allocated to direct activilies based oil the total direct costs of each fimction. T￿ecoverable VAT is charged as a cost against the activity for which the expenditure was incurred. Grant awards BSH invites applications for funding of research start-up grants for youiig investigators in haematology. BSH also aw&i'ds Student sc1)olat￿lilpS and scliolarsliips to assist Iiaemalology pi'ofessionals to visil overseas instiNtions foi. tlie puipose of learning new res¢Arcli or clinical tecliniques. In addition, BSH awai'ds ti'avel scliolar511ips to enable l)aeniatology nurses, physician associates, S￿dentS, doctoi's or sci¢ntisls iii li'aining to attend oveiEeas meetings. Applications ai'¢ made to 11)e Researcl) and Grants Coinmittee, whicl) is assisted by independent expert reviewei's foi. Ilie liigl)er-value researcl) grants. Tlie Board of Trusiees approves annual gi'aiit budB¢ls and ieviews expenditure re8ularly, Tlie liability for the grant is recognised at ilie point the relevant committees authoi-ise the award of tlie gi?nt. Oper2tlng leases Rentals payable under operating leases are ¢har8ed to the statement of fin&neial activities ovei. iEie tern)s of tlL¢ lease. s110rt-ter￿ beiiefits Sliorl lerni benefits, incliiding lioliday pay, are recognised as an expense in the pei'iod in whicli the seivice is received. PellSAons Tlie Charity conts'ibutes lo the NEST defmed contribution scheine, contributions inade in accord%n¢e with the niles of tlie plan and al'e charged to expenditure when Iliey are payable. Employee termiiiatlon benefits Tertllination benefits &re accounted for on an accrnal basis and in line with FRS 102. 25 Rcgi8tei'ed compally number.. 02645706

The British Society foi. Haeinatology (Li￿lted by guarantee) Note5 to tke financi￿1 Statements (coiiliFiiied) Yeai. elided 30 SepÉeu)bei' 2024 ACCOUNTING POLICIES (continued) Filed asset investments Quoted investments are stated at Anai'ket value at the balance sheet date. The investment in the subsidiaiy company is included in the accounts at cost. Fixed 9ssets and depreclation Items are capitalised if cost is greater than £1,000, othelvise they 8re written off directly to tlie Statement of Financial Activities. Depreciation on these assets is provided to write off the cost of taiigible fixed assels by eq1￿1 instaIments ovei. theii. estimated useful econon)ic lives as follows- Long leasehold pft)perty - over 50 years Office equipinent - 200/0 per annum TAxatlon The Society was registered as a charity in November 1991. Under s505 ICTA 1988 tlie charity is not subject to taxation on its charitable activities, The profits of the non-charitable subsidiary are gift aided to the parent company at the Dii'ectors, discretion. Any surplus ren)aining is subject to a taxation chai'ge. The chai'ge for taxation is based on the i'esull for the year. riund accountlng Tl)e Society Ilas the following types of funds for wliicli it is responsible aiid whicli require sepai'ate disclosures.. Genei'al funds General fuiids are unr¢stricled funds, and t]iese are expendable al the discretion of tlie Trustees in fijrthei'ance of tlie objectives of tlie company. In addition to expenditure oi) tlie prkncipal objectives of tlie conipany, sucli ￿ndS may be lield in order to finance capital investment and working capital. Deslgnated funds Desigtiated fijnds coniprise uwrstricted ￿ndS that have been set aside by tlie Tivstees foi. particulai. puiyoses. Restricted funds R¢stricted thnds are funds subjected to specific instructions by the donor, but still within tlie objects of tbe charity. Transfei's between i'eserves Tiansfeis between genernl and designated funds are made at the Trusie¢s' discretion to set aside funds as required, Financial Instruments The charity only Iiolds fillancial assets and fmancial tiabilitÈes of a kind tiiat qualify as basic fLnanci81 instiijnients. Basic fmancial instriiinenls include trade debt0￿, acciued income, otlier debtoi's and loan amounts due fi'ffln subsidiary undertakings. Basic fin8ncAal liabilities include trade credito￿, ac¢n￿lS, and other ei'editoi's. Basic financial instruments al'e initially recognlsed al transaction value and subsequently me&sured at thell. settlement value. 26 RegISl￿'ed company nutnber.. 02645706

The Bi'itish Society Cor Haematology ILi]llited by gugrantee) Notes to the financial statemeiits (6011liiiued) Year ended 30 Septeinber 2024 Debtors Ti'ade and other debtors are recogDised at the settlement due after any trade discount offeied. Prepayiiients valued at the aillount prepaid net of any trade discounts due. Creditoi's and pi'ovislons Ci-editors and provisions are recognised whei-e the charity lias a present obligation resulting froin a p&gt event that will probably i'esult in the transfer funds to a tl)ird paty and the atnount due to settle the obligation can be measured or estimated reliably. Creditors and piY)visions are noiinally recognised at tlieir settleinent ainount after allowing foi. any trade discounts due. DONATIOIYS 2024 2023 Re$trleted fuiids Donations 266,371 Total donatlons 266,371 OTHER tNCOME 2024 2023 Genei'al funds Sundry income 35 35 INVESTMENT INCOME 2024 2023 Genei'al funds Dividcnd and reNrns from investments Ollier interest receivable 87,981 74,700 78,791 60,291 162.681 139,082 27 Registered coinpany number: 02645706

The British Society for Haematology (LlIMRted by guai'antee) Notes (o the f￿8￿claI statements (coiilijiiigd) YeAr ended 30 Septeiiiber 2024 2024 2023 Rese￿.ch is aChIe￿d t]￿Ough tlK ￿Yment of following g'ants: E4rly Strg¢ ResearclTr start up grant (2023.. wt repwd) BSH-ASH Abstr8Gt AChIe￿￿)rnI ri'av¢l Scholarships StlldeDt electivcs BSH ASM Scliolar5hips' ]￿lUdIng for Stthnts Sciertlifie Meetinu sUp￿rt Visilii)g Fellow Oil)er Educational grants Globpj Ha¢maiology {DCSi￿ed Fund) Colioi't Study grant {from Desi￿]￿ed74￿lds) AI Fellowships Ifi'oin Designated Fthdg) 4 wts. 2023 0 grants I ￿lt. 2023 2 gra¢ 12 grattts. 2023 6 grants 28 ￿ants. 2023 23 grants 57 ￿. 2023 39 ￿'ants 2 grants. 2023 1 wattt J granl. 2023 1 ￿ant 18ranl' 2023 0 8ranLq 2023 4 ￿Ants 18ront' 2023 0 8Tattts I wt'2023 0 grants 142,031 4,326 8,830 21,250 22.008 2.000 17.520 566 (6,374) 8,706 5,636 20.897 16.611 1.000 15,000 40,519 51,493 82 270.106 101.995 Suppoit costs (see note 8) Blood Caicei. UK (froin De5i8naled FuThJs) 175.467 165,663 22,398 445 573 290 056 A totol of108 (2023.. 76) were a￿￿ded in the year. IrKluded in the aix)%¢ ar¢ Ib¢ following ￿ants pgid Éo inslitulioijs. All otliei. grants ftvmrded dir¢cily lo indivtdLials. 2024: Univei'sity of ca￿￿'1dgC £1,000. Kiii&q College £15.000. UnivErsity of York £40.000. James Hospil&l Board £15,000., Royol Coll¢g¢ of Pailiologists £500; UnI￿rs1ry of Oxford £51,493 2013: University of Oxford £1,000 28 Registered ¢omp2ny t]umb¢i': 02&15706

The British Society foi. Haemalologi, {Limited by guarantee) Notes to the financial state￿ell￿S (coiiliiiiied) Year ended 30 September 2024 EDUCATION AT+lD AWARENKSS 2024 2023 Guideliiies Costs.. Haemalologyllbroinbosis task force Lilei'ature Se￿.CbeS & Medical writlDg Digital Media costs Educational coiwnittee L£arning Manageinenl System costs External Affairs expenses Worktorce SUp￿rt Consultan¢y Paediati'ic SIG e￿nts Obsleli'ic SIG eNtnts tAb SIG t￿ntS Lab SIG Project Lyinphoiiia SIG events Early Cw'eeis Fonm SIG Global Hgemaiology SIG Progyaniine Con]mitlee expeA8es Educational Sei'vices & Jo￿l￿lS Anniial SGienc¢ Meeting Cosls Prizes & Excellencc Aivards Website Costs Educational E￿llIs Coslsl(Inconie) External e￿ftIS sponsoi'sl)ip Wilkinson Lectul'c cost (frojn DesI￿ted Funds) Workfoi'ce SurNty & C￿￿paIgning (Designated Fund) 691 52,600 8.450 1.151 2324 20,113 3.267 2,604 16,695 6,443 2,149 9,000 25,144 4,601 3,264 {280) 3,758 985 140 2,000 42.913 (150) 2,000 127 108,555 ,731 3,750 116,026 9,942 8,000 144 145.722 120,269 8,659 2,750 133,233 5,501 41,000 663 133,966 587.037 462,863 SuN)oi't costs (8¢e note 8) 970,915 916,667 1557 952 379 530 29 Registered company iiumbcr: 02645706

Tlie British Soeiety foi. Haematology ILlmited by guaraiitee) Notes to tbe financial statements (Loiilipiued) Yexr eihded 30 Septeinber 2024 EXPENDRTURK Dlyeet costs GrAnts payable Support eosts Tot911024 Cost of raising fimds liivesliiiekit niaiiageipieiiifee 14.396 23.396 37.792 Charitable activilies Reseaj'eh Ediicatioii aiid aHWi-eiiess Cost ofcopifei-eiiees 270,106 175.467 970,915 445,573 1557,952 1.022,116 587.037 ,022,116 1623 549 270 106 1 169778 3 063 433 EXPENDTfuRE PRIOR YEI AR Dlrect costs Graiits p&y8ble Support costs Tota12023 Cost of i'aising funds li?iieslJnepil I￿all&Selli¢￿1IeeS 14,530 22.088 36,618 Ch8ritable Aetivilies Reset7pth Ediicrttioii niid as￿l.elIe$S Cosl oJConfei'eiiL*s 22,398 462.863 929,373 101,995 165,663 916,667 290,056 1,379,530 929,373 1429 164 101995 1 104418 2 635 577 T5￿ basis of all￿allOn ot SUPEKSrt co$t$ is b18edon an allocation of ¢stiinated lime. Suppoi't costs - other 2024 2023 Salaries & other staff costs Pi'emises costs Office 4nd computing Pi'ofessional fees Mai'keling OtlLer 841.070 65,908 73,820 43,286 22.909 13 1,056.206 796.830 76,853 78,865 30,063 18,647 12,529 1,013,787 Suppoi't eo$t$- governance Aiidit costs Legal c0518 TKustees' & GO￿[n￿nce meetings 13,230 29.407 13,600 15,127 61,904 90,631 113,572 1 169778 1 104418 30 RegisteTed cothp&lly number.. 02645706

The British SocÉety for Haematology (Limlted by guarantee) Notes to the fiDancial statements (coiiliFiiied) Yeai. ended 30 Septeii)beJ' 2024 tNVESTMENT AND OPERATIONS IN TRADtNG SUBSIDIARY The wholly owned trading subsidiary, BSH Ente￿riSes Limited (02677826), which is incoi'porated in the United Kingdom and i'egistered in England and Wales, pays its profTt by gift aid at the discretion of the Dii'ectois. BSH Enteipiises Limited op￿.ateS the Annual Scieiitific Meeting (ASM) and all conimercial trading op￿ations. The chai'ity owns the entire issued shal'e capital of 2 ordinary shares of £1 each. A swnmary of tbe ￿dIng results is shown below.. 2024 2023 Turnovei. Cost of sales Gross {loss)Iprofit Athillnisti.atI￿ expenses Opci'ating (loss)/profit Finance Costs Interest receivable Profitl(loss) on ordinaiy activities before taxalion T8xation Gift Aid paid 1,539,731 1006,648 533,083 1,363,672 913,786 449,886 19,985 429,901 (1,242) 138 428,797 513,367 (1,512) 305 512,160 (430,692) (155,677) 81,468 273 120 Tlie assets and liabilities of the subsidiary were: Curi'ent assets due witliin one year Debtoi's due afteL' more th￿] one year Creditors: ￿liOl￿tS falling due within oDe year 678,077 669,791 667 127 585,661 SI1￿.e capital and reserNts 667 127 585 661 31 Registered company niullber: 02645706

Tlie British Soclety for HaematDlogy (Limited by guai'antee) Notes to tl)e finaiieial statcrnents (coiiliJiiiEd) Ye&r ended 30 September 2024 I O. NET INCOME 2024 2023 Net income is stated after cl)arging: Auditors. remuneration.. Audit of these financial st&temeiits (excluding VAT) Aiidit the subsidiary financial statements (excluding VAT) Other sei'vices Depirciatio 12,000 6,800 2,600 17,706 ii,ioo 6,230 2,500 20,172 REMUNERATION OF TRUSTEES The Ti￿StetS received no reniuneration during the y¢ar, or the previous period. I I TLlJStees received reimbursement of expenses in the year of £7,301 (2023.. 10 Tnjstees, £4,877) These expeiises r¢lated to travel and subsistence necessarily incuriEd iii the perfonnance of their duties. No amounts were paid directly to third parties. 12. STAFF NUMBERS AND COSTS The average number of persons, employed by the group during the year (excluding Trustees and Directors) was 15 (2023., 14). The avcr&g¢ number of persons including temporary staff was 17. The group aggregate pa￿.011 costs of these persons Were as follows: 2024 2023 Wages 8nd Salaries Social security costs Employers ￿￿$lon 'reInpor￿Y staff 581,284 56,298 42,170 73,015 557,676 54,882 39,740 77,023 752 767 729 321 There Mrie no employees ￿Ose emoluments for the year were betvKen £60,000 - £70,000 (2023.1 £60,000- £70,000). The key management peisonnel of the group includes the Tr￿Stees and Dii'ectors of tbe Senioi. Management Team. No tnjstees were i'emunei"ated during the Ye￿ (2023: nil). Th¢ total iemuneration to the key management personnel w&s £318,703 (2023.. £265,312) 13. TAXATIOIN Tlie company, wl)icb is a registered charity, is not liable io taxation on the net income frolll its chaiitable activities. 32 R¢gistered Cotllpauy number.. 02645706

The British Society for Haematology (Liinited by guarautee) Notes to the financial statemeiits (coiplipiiied) Yeai. elided 30 Septoinber 2024 14. TANGLBLE FIXED ASSETS Property & improvemellts Office Equipment Total 2024 Group and Charitable Company Cost At l October 2023 Additions Disposals At 30 Septeniber 2024 61M,759 2,136 54,490 659,249 2.136 606,895 54,490 661385 Depi'eciation At l Octobei. 2023 a]arge foi" the year Depi'eciation on diswsals At 30 Septeniber 2024 205,973 13,904 47,335 3,802 253,308 17,706 219,877 51,137 271,014 Net Book Value At 30 Septeniber 2024 387,018 390 371 At 30 Septembei. 2023 398 786 405 941 33 Regislei'ed compally number.. 02645706

The Brltlsh So¢lety for H8eD14tology (Limited by guai'4nteÈ) Notes to the llnAnelal statements (coiiliii£ied) Year elided 30 Septembei. 2024 Is. ri IXED ASSET INVESIMENTS 2024 2023 Group Investments at l October 2023 Additions Disposals Realised gainl(losses) Ut]realis¢d gains Total ]nvestments (excluding casli) Casli held in In￿Stment portfolio at 30 Sepiembei. 2024 Unllsted investments at l Octobei. 2023 Additio at 30 September 2024 8,100,743 1,699,481 (1,635,986) 97,856 956,919 9,219,013 28,179 9,247,192 7,696,016 1,929,731 (1,732,812) 16,113 91,695 8,100,743 17,878 8,118,621 101 loi ioi loi Total Investments at the end of the year 9,247,293 8,118,722 Historical costs of listed invcstments are £2,867213 (2023,. £2,700,523) Charitable compr4ny Listed Investments At l Octob¢r 2023 Additions Disposals Realised gainsl{losses) Unrealised gains Total Investmcnls (excluding casli) Cash held in inNEStinent portfolio At 30 September 2024 8,100,743 1,699,481 (1,635,986) 97,856 956,919 9,219,013 28,179 9,247 192 7,696,016 1,929,731 (1,732,812) 16,113 191,695 8,100,743 8 118,621 Unl isted iiivestments At l October 2023 Additions At 30 September 2024 103 103 103 103 Total Investments at end of year 9,247,295 8,118,724 The charitable company owns the entire sbare capital (two £1 ordinary shares) of BSH Enteiprises Limited, a ¢oinpany i'egistered in EnglaDd and Wajes. The Company orgallises confeitnces on behalf of tlie Biicish Society for Haematology. The results of the company are consolidated in these financial ststemenls. The charitable company also owns lOO/o of the sbare capitsl (101 £1 ordinary shal'es) of The Angel Office Village Ltd, a company i'e8lStered in EnglaDd alld Wales. 34 Registered eompany number: 02645706

The Britisli Society for Haematology (Limited by guat'aiitee) F4otes to the finaIici#l Stateineiits (eolilipiiied) Yegr ended 30 Septembei. 2024 16. DEB TORS Charitable c4Jmp&ny 2024 Group 2024 2023 2&13 Due in less Ilian ￿oI Trade debt013 Prepayi]]ents and a¢¢n￿d iocome Other taxes and social secwity An)0￿)IS due from sllbsidiary undeitaking 2,912 404,959 10,179 17,896 437,194 2.111 404,959 420,788 404,959 420,788 418,050 457,201 DI￿ in more ihan one year.. Prepaytnents and accru¢d income 1,272 11,272 To181 debtors 404,9S9 432,060 418,050 408.473 17. CREDITORS: Amounts fAlllng duc Cli4rltAble company 2024 Group 2024 2013 2023 ii'ithln one ye81. Il'ade ei'editois Other (axes 8nd social s¢¢urity 011)er creditors ACCri￿lS for ￿antS payablc ACC￿￿15 atid defei'i'ed incoinc (see belov4 Iiounls owed lo subsidiary utttkrtaking 45,056 79,199 6,672 18.855 225,491 71,411 86,832 6.958 71,337 207,208 46,106 79,199 6,672 18,855 235,391 82.693 86,832 6,958 71,337 280,056 375,273 443 746 386 223 527 876 Deferi'ed lii¢omÈ Subsci'iption income Other deferred ii)come TotAI$ A¢¢n￿lS Total #eeru&ls and deferred Incoiiie 65.901 62,765 65,901 62,765 3,140 65,905 214 151 280 056 73.741 151750 225491 65,905 141,303 207 208 73,741 161650 235,391 Defeii'edsubs¢i'iplioii i￿oIne o¢¢urs as subscriptiolls arc billcd bas¢d on tIK ¢alendaJ' year. Ti￿ee inonil)s' wvrth of the 2024 subscription income is deferrcd io the ?.0?.4125 financial y¢aY. Other deferred incotne relates lo re¢eipts foi. educalioi)al ¢ourses takingplacc the nex( financial period 35 RegISt￿Ed Company number: 02645706

The British Society for Haeniatology (Lirnited by guai'aiitee) Notes to the finaneial statements (coiiliiiued) Yeai- elided 30 Septeniber 2024 18. TOTAL FUNDS DesRgnated Restricted fund Geiieral funds Tolyl 2024 Croup At l October 2023 Net incoiiiel{cxpcndilurc) Re￿[VatiOn of in￿sIn￿nIS (ThJt¢ 15) Trathsfct3 betM¢ell fun At 30 September 2024 387.542 (186,204) 10.766,252 154,627 1,054,727 1,153,794 234,794 I,054,727 266.371 201 J38 266.371 11.975,606 12,443,315 Cliai'ltlble cortipamy At l October 2023 N¢t iJi¢omellexpendilwe) Re￿[1￿[loTh of in￿SIn￿ntS (not¢ 15) Tr&&8fers between furLd8 At 30 Septenita. 2024 387.542 (186,2041 10.180,593 73,161 1.054,727 10,568,135 153.328 I,OS4,727 266,371 201.338 266J71 11,308.481 11,776,190 Dcslgllattd funds Net outgoliig TransfeY5 fronil resei'ves (to) General funda Jjglallce At 30 Sep 2024 l Oet 2023 Gi'oup 8iid t11￿.It￿b1e company Wilkinson B¢qu¢8t Cohort Study IDat2 Re￿Stry Project FutM]I Rcgional Ents Suywrt Fur¥1 14aemalogickl Workforce Sursry Pfojeel AI Felloivahip Aw4rds Tot911 21,S31 51,733 20,IJOO 204,278 1663) {51.493) 20,8611 240 20,000 70.312 1133.966> 82 186204 387 542 201338 Desl nated fi unds Til¢ Wilkinson Bcquesl is a dcsi¥Daled fund ￿ll¢h PAYS for tbe Sir John Dacic Lcc¢ur¢ by an inteimational s￿aker at tlie ASM, in Since the Workforce Repjrt wa8 pvblisl]ed in 2020, the BSH has commissioned 8 major research pi'oject to ii)stigat¢ the cwi'ei)t state of Ihe Iiacmatology ￿rkforce, Il)¢ Hrllbeing of the muliidisciplinary te￿n (MDD and Iiow good praolice cati help Ilie rkfoi'ce crisis; Ilie Bo8rd had Set aside funds of £350,000 towards this ￿￿j¢¢t. lie Col)oi'l Study (Dats Registry Proj¢cl) Fund- s¢¢ w) to SLWM)rt colK)rt stwlies. The moncy be¢ii w8ed a8 p&rt of the Soci¢ly's r¢search programine, and the final &W￿.d has noiybeen PAid. Region81 Eveiits supp)it- to sutq)ort ¢(iucatiOil 8cross the UK. BSH members Mll be able to at4)ly to the f￿￿ to supp)rl initiati￿S in ih¢ii' part of tlie country. In September 2023 the Boord weed to fiuMI BSH fc110￿ to VA)rk for a year oll Al wijects specifically ali8ned witli clinical liaeinalology, in partnei'ship with pro￿.a￿￿¢ by the Clinical Scienlific ComputiugTegm bosed at Guy's & St llwn)&8' Foundation TA￿¢. Restricted Funds l]ie UK MDS Forutn was gI￿n a l¢gacy Ik)nation Ilwough a ￿lie0¢ that p&ssed aMy from mYelod￿pLIStie syndromc ar￿ tlKs¢ fw]ds, along Witli the reniaining capilal froin the UK MDS Forum charity ac¢oullL were trw]sferred lo Ihc BSH and held in a Rcstri¢led fund for the recently formed MDS s￿¢1￿1 Interest Group. The fi]n(Ls gre to be w8¢d for the illedical cat¢, cduc8tioD at]d rcscai'ch relatimg to myelodysplasli¢ syndroine. The MDS Special Inleresl Group ivltbin the BSH will ￿ restX)JLsible for woposals to utilisc Éhese funds, ￿)ich will be approved by th¢ Trnstees. 36 Registcred conipany iiumber: 02645706

The Britisli Society for Haem%tology (Limited by guarantee) Notes to tbe finallcial 5tatcineDts (coiilijiiied) Year eDded 30 Septembei. 2024 18. TOTAL fiUE4DS PIUOR YEAR Desigllated fitnds General ￿lld$ Resti'leted Fund6 Total 2023 CrDUP At l OCto￿r 2022 Nel incoinellexpenditure) ReNaluation of tnwSln￿nts {not8 15) Transfcrs bctmteii fuuds At 30 September 2023 149,885 {208.783) 10,591,437 413,442 207.813 1446,440) 10,766,252 10.741,322 204,659 207.813 446.440 387542 11.153,794 Chai'ltable eoitspsny Al l (k,lober 2022 Net iii¢omel(expcndibxel RevJliJalion ot lil￿stn7e￿tS (note 15) Tr¥rK%fers beiRren fwids At 30 S¢ptcrnber 2023 149885 (208.783) 10278.898 140.322 207,813 (446,440) JO.180,593 10,428,783 (68.461) 207,813 440,440 387.542 10,568,135 DÉAIEnated fljnth BAlance at l Oci 2022 Net ouigoliig re5ei.ves Transfers from Gtneral funds B8]￿liCe 8t JO Sep 2(llJ Group 8nd cli#Yitable eomp8ny Global Hoeiiiatology Fw Wilkirtqoii Bequest Colioit Study (Daia Registry Proj¢¢t Fund) Blood Cancer UK FiirLd Regional E￿nIS Support FuNi Haen)Nlogieai Workforce Sumy Project Al Fello1￿liip Awar Tot#ls 34,079 21,675 51,733 22.398 20,000 (40,519) (144) 6.440 21,531 51,733 {22,398) 20,000 204,278 90,000 387 542 {145.722) 350,000 90,000 446 440 149,885 208,783 19. AP4IlLYSIS OF GROUP NET ASSE15 BEIWEEN FUNDS Deslgngt¢d Funds Genei'AI Furtth Re5ti'itted Fund5 Total 2023 F￿11￿ b919n¢es at 30 September 2024 *re i'epreseiiled by: Tangibl¢ fix¢d assets In￿slinentS Currenl asse15 (liabilities) At 30 September 2024 390371 9,247,293 2 337 942 11975.606 390,371 9247,293 2 805 651 12443,315 201 38 201.338 266371 266371 ANALISIS OF GROUP NET BKTWEEN FUNDS- PRIOR YEAR Designated Funds General Funds Re5trlcled Furtds Tot 2023 ri und bAlance8 8130 S¢ptember 2023 are represciited by,. Ta3Jgible fiK¢d assets Jn¥estments Cuileni assets {liabilities) At 30 Septembey 2023 405,941 8,118.722 2241589 10,766.252 405,941 8,118,722 2629 131 11 153.794 387.542 387 42 37 Registered ¢onipally number.. 02645706

The Brltlsh Society for HaemAtology ILimited by gu￿1.￿￿tee} Notes to the Ilnanelal stalemenls (eoiiliiiiied) Ye4r ended 30 September 2024 20, OPEI RATING LEASE COMiI(ITMEIYTS As at 30 Septeinber 2024, the charity and group's futui'e minimum operating lease payments ￿'e as follows.. 2024 Charlly 2023 Charlty Group Gj'oup Office Equlpment Witl)in one year BetNNeen tw) aud fi￿ years 516 516 1,032 516 516 719 719 1,032 Ilie Iimounts charged to the St*emenl of Finartial Aclivilies in the year w&q £516 (2023: £516) 21. PENSIONS Tlie Charity Contribut￿ lo the NEST pension scheme. This is a defined conli'ibution sclien)e, conti'ibutions al-e made iii accordance witli tlie rules of the plan ai)d are cliarged to expenditsjre wl)en tliey al-e payable. Conti'ibulions to Ilie scheme totalled £42.170 (2023.. £39,740). At tlie year end contributions totalling £4,397 (2023: £5,191) were outstanding. 22. RELA TED PARTY TRANSACTIONS No related paty ti'ansactions look place in the year (2023: none), 23. POST BALANCE SHII ET EVENTS After tlie year end a ￿rtIle1. £7,037 was received relating to the UKMDS legacy. 38 Registered cornpany nu]nber: 02645706

Tl)e Bi'itish Society for Haemalolog), (Lilliiled by guai'antee) CoJ)solidgted statoiiient of financial activities Yeai. ended 30 Septeniber 2024 24, PIUOR YEAR sfAIEMENT OF FINANCIALAciivfiiES Cener#l ri und$ Desl8nated Funds Totgl 2023 Notes Income from Donatio Cliarilable aclivilie&.- Siibs¢rii)tions Profit sliare of British Joumal of Haetth8tologJ Other ii]co]nc JTLcome fi'oin the operation of confer¢￿e$ InNtslment income Total Inc4)me 243.874 1.093,573 35 1.363.672 139,082 2.840,236 243,874 1.093.573 35 1,363,672 139,082 2 840 236 EXPENDITURE 0Tr4: Raibiiig funds In￿st￿]ertt i?)anagen)eiit fees 36,618 36.618 Charitable aetivities Research Education ¥And Awareness Cost of operation of confcrcnces 618 227.139 ,233.664 929,373 62.917 A45,866 290,056 1,379,530 929,373 Total expendlture 2 426 794 208 783 2 035 577 Net lttcome before Investment and tramsfers 413.442 (208,783) 204,659 Net gaills on illiwlmenls 207,813 207.813 Net Inconie And net movements In funds 621,25S (208.783) 412,472 Transfer beMren funds (446,440) 446,440 Reconelllation of funds Fulld balances broughl forward 10,591,437 149,885 10,741,322 Fut]d ￿Art¢es ¢wYied fonvard 18 10.766 252 387 42 11 153794 All recognised gains and losses are reflec*d througli tlie Stateinent of Finaiicial Activilies. All activities reflected above are continuing activities. 39 Registered conipany i)umb¢r'. 02645706